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Abstract
The G protein-coupled receptor (GPCR) family is composed of hundreds of
members and is expressed in eukaryotes. Each GPCR has seven transmembrane domains
and is in charge of sensing changes from the environment, transducing signals, and
activating a series of biological responses. The signal transduction pathway of the
receptor starts from sensing outside signal and then activates G proteins. This signaling
requires a tight control for activation without which impaired cellular function leads to
pathology. We have used the pheromone alpha-factor receptor (Ste2p) of the yeast
Saccharomyces cerevisiae as a model system to understand ligand binding, receptor
activation, and G protein interaction. One method we have used to study ligand binding is
to incorporate the photo-reactive crosslinker p-benzoyl-L-phenylalanine (Bpa) into Ste2p
to capture alpha-factor. This powerful tool requires the incorporation of Bpa, an unnatural
amino acid, into Ste2p by a special genetic manipulation designed in the lab of Peter
Schulz (Scripps Institute) and adapted by our lab for Ste2p. Another method to study
ligand binding that we have adapted for use in our system is to incorporate a chemical
crosslinker [3,4-dihydroxylphenylacetyl (DHPA)] into alpha-factor for periodatemediated crosslinking to Ste2p. The interacting domain between alpha-factor and
transmembrane domain 2 to 3 of Ste2p was identified after DOPAC crosslinking,
cyanogen bromide digestion and MALDI-TOF mass spectrometry. After ligand binding,
signal transduction is mediated by the interaction of activated Ste2p with its G protein
(Gpa1p). We studied this interaction by replacing natural residues in the intracellular loop
3 of Ste2p and C-terminal end of Gpa1p with cysteine and then determining disulfide
crosslinking between Ste2p and Gpa1p. Some residues were found to be in close
proximity and displayed different interacting patterns due to conformational changes of
the receptor upon ligand binding. The information we gathered here allows us to
understand more about the physical interactions of alpha-factor, Ste2p, and Gpa1p and
provides us insights about the initiation and activation of the signal transduction pathway
of a peptide ligand receptor.
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PART I
General Introduction
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Chapter 1
G Protein-Coupled Receptors: An Overview
Basic Information about G-Protein-Coupled Receptors
G protein-coupled receptors (GPCRs) are characterized by seven transmembrane
domains with an extracellular N-terminus and intracellular C-terminus (1). The main
function of a GPCR is to transduce extracellular signals into the cytoplasm of the cells
and activate a variety of cellular responses according to different environmental stimuli.
GPCRs control our sensations of vision, smell, taste, and pain (2), as well as responses to
hormones and neurotransmitters (3). They are among the largest and most diverse protein
families in mammalian genomes and represent targets for approximately 40% of all
marketed drugs.
GPCRs serve as regulators with special structural motifs to interact with both
extracellular ligands and intracellular proteins (4). A study examining the structure
domains of three GPCRs, rhodopsin, thyrotropin stimulating hormone (TSH) receptors,
and vasopressin 2 (V2) receptors, has revealed that genetic variations affect the receptors
in ligand binding and G protein coupling (5). As the matter of relationships between
GPCR structures and functions, the N-terminus and extracellular domains of GPCRs are
suggested to play roles in ligand binding, intracellular trafficking, and down-regulation
(6). Helix-helix interactions in the transmembrane domains are important to maintain the
stability of the receptors in preferred structures for ligand binding and activation (7).
Intracellular loop domains are essential for G protein interactions and signal transduction
(8-10). Some receptors appear to exist as homodimers and heterodimers (11), such as the
2

GABAB receptor (12), and oligomeric assembly affects the receptor biosynthetic steps of
maturation and trafficking and internalization internalization during down-regulation
after signaling occurs.

GPCR Crystal Structure
Rhodopsin was the first GPCR structure to be crystallized (13), which set up the
cornerstone for providing insights about receptor activation and interactions with ligand
and G proteins. In addition to rhodopsin, crystal structures of β1 and β2-adrenergic
receptors (14-16), adenosine receptor (17), CXCR4 chemokine receptor(18), Dopamine
D3 receptor (19), and Histamine H1 receptor (20) have also been recently obtained. With
the increasing availability of GPCR crystal structures, some of the key issues in GPCR
biology, such as the ligand-binding pocket, extracellular disulfide bridges, and
transmembrane domains orientations, have been elucidated (21). The information of
three-dimensional GPCR structure supports homology modeling studies and benefits
structure-based drug design (22).

Lignand binding domain of GPCR crystal structures
Rhodopsin consists of the chromophore 11-cis-retinal covalently linked with the
protein opsin at the lysine residue at position 296 (13). Absorption of a photon changes
the conformation of chromophore to all-trans-retinal and results in activation of
Rhodopsin. According to the crystal structure of rhodoposin, several residues (Tyr43,
Met44, Leu47, Thr94, Glu113, Gly114, Ala117, Thr118, Gly120, Gly121, Glu122, Cys167, Ser186,
3

Cys187, Gly188, Ile189, Tyr191, Met207, His211, Phe212, Phe261, Trp265, Tyr268, Ala269, and
Phe293) from extracellular loops and transmembrane domains form the binding pocket for
the chromophore.
The β1-adrenergic receptor couples to the Gs pathway (adenylyl cyclase, cAMP,
and protein kinase A) in cardiac cells, which when activated increases the heart rate (23)
and induces myocyte hypertrophy and apoptosis by Gs-protein kinase A-independent
activation of calmodulinkinase II signaling. The β2-adrenergic receptor couples to Gs and
Gi pathway and protects cardiomyocytes from apoptosis via a Gi–phosphatidylinositol 3
kinase (PI3K) pathway (24). The crystal structure of human β2-adrenergic receptor (14)
reveals extensive interactions between the receptor and the ligand, carazolol, at positions
Trp286, Phe289, and Phe290. The direct interaction between the receptor and carazolol is
through an aromatic interaction with Phe193 at extracellular loop 2 (EL2) (25). The
common binding pocket for timolol and carazolo includes Asp113, Asn312, and Tyr316.
Timolol binds deeper into the receptor pocket and forms a polar interaction with Asn293,
which allows an additional hydrogen bonding interaction with Thr118 (26). In human β1adrenergic receptor, similar to that of carazolol in β2-adrenergic receptor, the ligand
biding pocket includes Asp121, Phe201, Thr203, Ser211, and Asn329 (15). The Ser211 residue
displays ligand-induced rotamer conformational changes to stabilize the binding pocket.
Adenosine receptors play an essential role in responding to adenosine in the
central nervous system and are major targets of caffeine (27). The ligand binding pocket
of A2A Adenosine receptor for the antagonist theophylline (ZM241385) has been
identified (17) to reside at Phe168, Glu169, Trp246, Leu249, His250, Asn253, His264, Leu267,
4

Met270, and Ile274. The agonist (UK-432097) binds into the A2A Adenosine receptor at
Tyr9, Ala63, Val84, Leu85, Thr88, Glu169, Met177, Trp246, Leu249, His250, Asn253, His264,
Leu267, Met270, Tyr271, Ser277, and His278 (28). The residues Glu169 (EL2), Tyr197 (TM6),
and Phe201 (TM6) function as switches for rotamer conformation after ligand binding.

Transmembrane domain (TM) interaction of GPCR crystal structures
According to the crystal structure of rhodopsin (13), interactions among
transmembrane domains (Leu40-Phe293-Phe294- Cys264, Asn55-Asp83-Ala299, Asn73- Tyr306,
Asn78- Ser127-Thr160-Trp161, Asp83-Gly120, Cys110-Cys187, Glu122-Met163-His211, Glu134Arg135-Glu247-Thr251) was observed to stabilize the inactive structure. The (D/E)R(Y/W)
motif (Glu134-Arg135-Tyr136) forms hydrogen bonds with surrounding residues. The
tripeptide sequence Val137-Val138-Val139 covers the cytoplasmic side of Glu134 and Arg135
and maintains the conformation of rhodopdin. Photoactivation is likely to interfere with
the transmembrane constrains, such as Phe294, Ala299, Asn302, and Tyr306, and unfold the
active conformation.
In human β2-adrenergic receptor (14), there are two disulfide bonds (Cys184Cys190 and Cys191-Cys106) stabilizing extracellular loop 2. The interactions among
Trp286, Phe289, and Phe290 constrain the inactive state of the receptor. There are ionic
interactions and salt bridges between residues at different TM domains (Lys60-Glu338 and
Lys305-Asp192) to maintain the receptor structure (25). Upon ligand binding in the β1adrenergic receptor, Ser212 forms a hydrogen bond with Asn310 (29) and the rotamer
change of Ser215 appears to break the interaction of Val172-Ser215. Also Tyr149 forms a
5

hydrogen bond with Asp138 (15). A short α-helix in intracellular loop 2 interacts directly
with the highly conserved Asp138-Arg139-Tyr140 (DRY) motif in TM3 (15).
Adenosine receptor forms hydrogen bonds in Asp101-Tyr112-Thr41 and disulfide
bonds at Cys71-Cys159, Cys74-Cys146, Cys77-Cys166, and Cys259-Cys262 (17). The D/ERY
(Asp101-Arg102-Tyr103) motif plays a role in stabilizing the polar interactions with TM2
(Thr41), IL2 (Tyr112), and TM6 (Glu228), which possibly modulates G protein activation.
There are interactions at IL2 (Tyr112-Asp138) and Thr88-Ser277-His278. Upon ligand
binding, the residue His250 moves ~1.8 Å inward and Trp246 indole moves ~1.9 Å to avoid
the steric clash with the ligand (28). The conserved NPxxY motif composed of Asn284,
Pro285, Phe286, Ile287, and Tyr288 at the cytoplasmic end of TM7 shifts about 4 to 5 Å
inward, resulting in reorganizations of these side chains, especially at the residue Tyr288.

G protein interaction of GPCR crystal structures
In all GPCRs, intracellular loops, especially IL2 and IL3, are critical to activate
and provide variability among related GPCRs as a result to specific G-protein activation
(13, 15). The C-terminal end of rhodopsin is surrounded by hydrophobic residues from
TM2 (Pro71, Leu72), intracellular loop 2 (Phe148), TM5 (Leu226, Val230), and TM6 (Val250,
Met253), forming the binding site for a G protein (13). In the β1-adrenergic receptor
(Warne 2008 Nature 486), intracellular loop 2 is proposed to play a key role in G-protein
coupling and activation (15).
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Chapter 2
Alpha-factor Pheromone and its G Protein-coupled Receptor (Ste2p) of
Saccharomyces cerevisiae
Yeast Mating Pheromone Response Pathway
In yeast two distinct GPCR systems have been identified: one is for pheromone
signaling (Figure 1.1) and the other is for glucose sensing (30). Our lab uses the
pheromone response pathway in Saccharomyces cerevisiae as a model system for the
study of GPCR-ligand interaction. The MATα cell generates the 13-residue peptide
[WHWLQLKPGQPMY] α-factor, which activates the Ste2p receptor on the MATa cell.
The

MATa

cell

generates

the

12-residue

lipopeptide

[YIIKGVFWDPAC(farnesyl)OCH3] a-factor, which targets the Ste3p receptor on the
MATα cell (31). The two mating peptides bind to residues on the extracellular side of
receptors and cause conformational changes that transmit a signal to the G proteins inside
the cells.
G protein subunits serve as intermediate modulators between the cell surface
receptors and the intracellular effectors (32), transducing pheromone binding signal into
cytoplasmic response. Upon ligand binding, Gpa1p (Gα subunit) bound GDP is replaced
by GTP, and Ste4p/Ste18p (Gβγ subunits) are then released, which in turn transmits the
signal required for mating. Recent studies have shown that Gpa1p can also stimulate
downstream signaling. A GTPase-deficient mutant (GDP-bound form) of Gpa1p was
found to couple with an RNA binding protein Scp160 (33) and endosomal
phosphatidylinositol 3-kinase Vps15/Vps34 subunits (34), suggesting a role of Gpa1p not
7

only as a negative regulator of Ste4p/Ste18p (35, 36), but also as an inducer of the mating
signal pathway.

Figure 1.1 Components of the pheromone response pathway in yeast. This figure was
taken from reference (37).

Released Ste4p/Ste18p subunits transmit the signal to a mitogen-activated protein
(MAP) kinase cascade through at least three effector proteins (32): a guanine-nucleotide
exchange factor Cdc24p (38), a protein kinase Ste20p (39), and a kinase scaffolding
protein Ste5p (40). Cdc24p is the guanine nucleotide exchange factor for the Rho Gprotein Cdc42p (41); Cdc42p regulates MAP kinase signaling through PAK (p218

activated kinase)-family kinase Ste20p (42). After binding with Ste4p/Ste18p and
Cdc42p (43, 44), Ste20p activates the downstream MAP kinase cascade. Pheromone
response protein Ste5p serves as a scaffold (45, 46) to facilitate interactions among
member of the MAP kinase cascade: Ste11p (MAPKKK), Ste7p (MAPKK) and Fus3p
(MAPK). MAP kinase kinase kinase Ste11p phosphorylates MAP kinase kinase Ste7p,
and Ste7p phosphorylates MAP kinase Fus3p. Mating specific Fus3p then phosphorylates
Far1p (47) and Ste12p, a transcription factor (48). Far1p inhibits Cdc28-G1 cyclin
complex and promotes G1 cell cycle growth arrest (49). The transcriptional
transactivatior Ste12p binds to the pheromone response element (PRE) at the promoter
region of target genes (50), such as FUS1, FUS2, FIG1, FIG2, AGA1 that are induced for
cell fusion. MATa and MATα cells form shmoos with the apical tips directing toward
each other (51). Eventually at the contact points of two opposite mating types,
degradation of the cell wall and plasma membrane followed by nuclear fusion allow two
haploid cells to become one a/α diploid zygote (52).

Regulation of Mating Pheromone Response Pathway
Figure 1.2 summarizes the activation, desensitization, and internalization of the
Ste2p signaling pathway (53). Yeast cells start a mating cell cycle and trigger G1 growth
arrest when there is nutrient starvation or the presence of mating factor from the other
mating type (54). Eventually yeast cells would have to recover from mating state and
continue proliferation through the mitotic cell cycle (32). The MATa cell produces an
extracellular protease, Bar1p, which cleaves α-factor (55) and allow cells to recover from
9

α-factor induced growth arrest. Expression of RGS (regulator of G-protein signaling)
Sst2p is highly induced by the activation of Ste2p. Membrane-associate Sst2p is a direct
negative regulator (56) that interferes with GTP-bound Gpa1p and down-regulates mating
signal. Yeast casein kinases, Yck1p and Yck2p, are involved in bud morphogenesis and
internalization of pheromone receptors (57).

Yck-mediated phosphorylation of the

mating receptors is required for endocytosis at the cell membrane (58). Eventually
phosphorylation at the C-terminus of the receptor leads to ubiquination, internalization
and degradation (32).

Figure 1.2 Sst2-mediated activation, desensitization, and internalization of Ste2p.
This figure was taken from reference (53).
10
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PART II
Unnatural Amino Acid Replacement in a Yeast G Protein-Coupled
Receptor in its Native Environment
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Part II was published in its entirety as: Huang LY, Umanah G, Hauser M, Son C,
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determined the expression conditions and biological activities of all mutants. George K.
Umanah was responsible for the mass spectrometric and cross-linking studies. Boris
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pheromone peptides used in the study.
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Abstract for Part II
Ste2p is the G protein-coupled receptor (GPCR) for the tridecapeptide pheromone
alpha factor of Saccharomyces cerevisiae. This receptor-pheromone pair has been used
extensively as a paradigm for investigating GPCR structure and function. Expression in
yeast harboring a cognate tRNA/aminoacyl-tRNA synthetase pair specifically evolved to
incorporate p-benzoyl- l-phenylalanine (Bpa) in response to the amber codon allowed the
biosynthesis of Bpa-substituted Ste2p in its native cell. We replaced natural amino acid
residues in Ste2p with Bpa by engineering amber TAG stop codons into STE2 encoded
on a plasmid. Several of the expressed Bpa-substituted Ste2p receptors exhibited highaffinity ligand binding, and incorporation of Bpa into Ste2p influenced biological activity
as measured by growth arrest of whole cells in response to alpha factor. We found that, at
concentrations of 0.1-0.5 mM, a dipeptide containing Bpa could be used to enhance
delivery of Bpa into the cell, while at 2 mM, both dipeptide and Bpa were equally
effective. The application of a peptide delivery system for unnatural amino acids will
extend the use of the unnatural amino acid replacement methodology to amino acids that
are impermeable to yeast. Incorporation of Bpa into Ste2p was verified by mass
spectrometric analysis, and two Bpa-Ste2p mutants were able to selectively capture alpha
factor into the ligand-binding site after photoactivation. To our knowledge, this is the first
experimental evidence documenting an unnatural amino acid replacement in a GPCR
expressed in its native environment and the use of a mutated receptor to photocapture a
peptide ligand.
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Chapter 1
Introduction
G protein-coupled receptors (GPCRs) are activated upon binding their cognate
ligands. Ligand binding initiates a change in the conformation of these integral
membrane proteins. This promotes signal transduction across the membrane and the
activation of the G protein-mediated signal transduction cascade (1, 2). The interactions
between ligands and their receptors are defined for a number of GPCRs (3). However, the
ligand-induced changes in protein structure, which initiate signal transduction, are
difficult to study. Although site-directed mutagenesis has been used to address the issue
of GPCR activation, more methods for studying ligand-dependent conformational
changes upon receptor activation are needed. One promising approach, which may be
adapted to the study of the dynamics of the GPCR structure, is the use of orthogonal pairs
of tRNA/aminoacyl-tRNA synthetases evolved and expressed in the target cell to
incorporate unnatural amino acids (4-7).
Non-naturally occurring amino acids can be synthesized to contain a variety of
chemical moieties for use as photoaffinity labels or fluorescent and/or spectroscopic
probes. To autonomously incorporate unnatural amino acids into proteins in living cells,
the mutated tRNA is designed to recognize a specific codon, usually a nonsense codon,
such as the amber TAG stop. Provided that there is a sufficient quantity of the unnatural
amino acid in the cytoplasm, the evolved cognate aminoacyl-tRNA synthetase
specifically charges its orthogonal tRNA with this novel amino acid for delivery into the
protein.
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The genetic codes of Escherichia coli, yeast, and mammalian cells have been
altered to allow for the translational insertion of more than 30 unnatural amino acids with
a variety of novel properties useful in the study of protein structure and function(5, 8).
Thus far, these applications have focused primarily on soluble proteins. With respect to
eukaryotic membrane proteins expressed in mammalian cells, unnatural amino acids have
been introduced into the nicotinic acetycholine receptor in both CHO and cultured
neuronal cells (9) and in the epidermal growth factor receptor in HEK293 cells (10). A
heterologous Xenopus oocyte expression system has also been used extensively to insert
non-natural amino acids into the nicotinic acetylcholine receptor (11) the neurokinin-2
receptor (12), the GABAA receptor (13), the NMDA receptor (14), and numerous
channel proteins, including the serotonin-gated ion channel (15), the inwardly rectifying
potassium channel (16), and the voltage-sensitive sodium channel (17). In both the
mammalian and Xenopus expression systems, a tRNA chemically charged with the nonnatural amino acid is introduced into the cell along with the target mRNA. While these
systems are useful for the short-term studies of protein properties, they are not amenable
to large-scale production of proteins into which unnatural amino acids have been
incorporated. Recently, it was demonstrated in CHO cells that unnatural amino acids
could be introduced into green fluorescent protein (GFP) using specific orthogonal
tRNA/aminoacyl-tRNA synthetase pairs (6). Because the yeast Saccharomyces cerevisiae
provides a tractable system in which to develop this methodology, we report here the
genetic incorporation of an unnatural amino acid into a polytopic membrane protein in its
native eukaryotic host cell.
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To date in S. cerevisiae, orthologous tRNA/aminoacyl-tRNA synthetase pairs
have been used to incorporate a variety of unnatural amino acids, including the
photoactivatable amino acid analogue p-benzoyl-L-phenylalanine (Bpa) (4), the
fluorescent amino acid dansyl alanine (18), and acetylene- and azide-containing amino
acids (7, 19), into the soluble protein human superoxide dismutase. Here, we report the
site-specific incorporation of Bpa into Ste2p, a yeast GPCR, using an orthologous
tRNA/aminoacyl-tRNA synthetase pair. In this system, the amber TAG stop codon was
engineered into specific sites within the STE2 coding region. Bpa was supplied to the
cells either as the free amino acid analogue or as the dipeptide Met−Bpa. Upon
translation of the message, Bpa was incorporated into the nascent Ste2p and ultimately
expressed at the cell surface. Two of our Bpa−Ste2p receptors were used to selectively
photocapture biotinylated α factor. To our knowledge, this is the first report of the
expression in the native host cell of a GPCR containing a photoactivatable amino acid.
The successful photocapture of α factor by novel Ste2p mutants shows that GPCRs
containing unnatural amino acids can be used to capture ligand and study changes in
domain−domain interactions during GPCR activation.
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Chapter 2
Material and Methods
Media, Reagents, Strains, and Plasmids
S. cerevisiae strain DK102 (MATa, ura3−52 lys2−801am ade201oc trp1-Δ63 his3Δ200 leu2-Δ1 ste2::HIS3 sst1-Δ5) was used for growth arrest and binding assays, and the
protease-deficient strain BJS21 (MATa, prc1−407 prb1−1122 pep4−3 leu2 trp1 ura3−52
ste2::KanR) was used for protein isolation and immunoblot analysis. C-Terminal FLAG
and His-tagged STE2 was PCR-amplified from plasmid pNED1 (20) and cloned into the
plasmid p426-GPD (21) to yield plasmid pCL01. The plasmid pCL01 was engineered by
single-stranded mutagenesis to incorporate TAG stop codons at eight specific positions
within the STE2 coding region (Figure 2.1). The sequence of all TAG mutants was
verified by DNA sequence analysis completed by the Molecular Biology Resource
Facility located on the campus of the University of Tennessee. Mutagenic and sequencing
primers were purchased from Sigma/Genosys (The Woodlands, TX) or IDT (Coralville,
IA). The pCL01 TAG mutant plasmids were cotransformed by the method of Geitz (22)
into DK102 and BJS21 cells along with plasmid pECTyrRS/tRNACUA, encoding the
orthogonal amber suppressor tRNA synthetase−tRNA pair genetically modified to allow
for incorporation of p-benzoyl-L-phenylalanine (Bpa) (4). Transformants were selected
by growth on minimal medium (23) lacking tryptophan and uracil (designated as
MLWU) to maintain selection for the plasmids. Cells used in the assays described below
were cultured in MLWU and grown to mid-log phase at room temperature with shaking
(200 rpm) in the presence or absence of 2 mM Bpa, unless otherwise specified.
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Methionyl-Bpa was synthesized by standard solution phase techniques (24) and purified
by reverse-phase high-performance liquid chromatography (HPLC) to greater than 99%
homogeneity. All media components were obtained from BD (Franklin Lakes, NJ) and
were of the highest quality available. Bpa was purchased from Bachem (Torrance, CA)
and was dissolved in NaOH (1 N) at a final concentration of 100 mM immediately before
use.

Growth Arrest Assays
DK102 cells expressing the wild-type (WT) or TAG constructs were grown at
30°C in MLWU, harvested, washed 3 times with sterile water, and resuspended at a final
concentration of 5 × 106 cells/mL. Cells (1 mL) were combined with 3.5 mL agar noble
(1.1%) with or without the addition of Bpa (2 mM final concentration) and poured as a
top agar lawn onto MLWU medium. Filter disks (BD, Franklin Lakes, NJ) impregnated
with the tridecapeptide pheromone α factor (WHWLQLKPGQPNle12Y) synthesized and
characterized as previously described (25) were placed on the top agar, and the plates
were incubated at room temperature (23°C) for 48−72 h. The growth arrest assays were
repeated a minimum of 3 times, and similar results were observed for each replicate.

Immunoblots
BJS21 cells expressing WT or TAG-STE2 constructs grown in the presence or
absence of Bpa were used to prepare total cell membranes isolated as previously
described (20). The protein concentration was determined (BioRad, Hercules, CA), and
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membranes were solubilized in sodium dodecyl sulfate (SDS) sample buffer. Proteins (2
µg/lane for WT and 30 µg/lane for mutants) were fractioned by SDS−polyacrylamide gel
electrophoresis (PAGE) and immunoblotted. Blots were probed with FLAG antibody
(Sigma/Aldrich Chemical, St. Louis, MO) or an antibody directed against the N-terminal
100 amino acids of Ste2p generously provided by J. Konopka (26). The immunoblots
were imaged, and band density was quantitated using Quantity One software (version
4.5.1) on a Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA).
Multiple repeats of immunoblot experiments yielded the same results.

Binding Assays
Tritiated α factor (10.2 Ci/mmol, 12 µM) prepared as previously described (25)
was used in saturation binding assays on whole cells. DK102 cells expressing WT or
TAG constructs were harvested, washed 3 times with YM1 (20), and adjusted to a final
concentration of 2 × 107 cells/mL. Cells (600 µL) were combined with 150 µL of ice-cold
5× binding medium (YM1 plus protease inhibitors [YM1i (20)] supplemented with [3H]α
factor) and incubated at room temperature for 30 min. The final concentration of [3H]α
factor ranged from 0.5 × 10−10 to 1 × 10−6 M. Upon completion of the incubation interval,
200 µL aliquots of the cell−pheromone mixture were collected in triplicate and washed
over glass fiber filter mats using the Standard Cell Harvester (Skatron Instruments,
Sterling, VA). Retained radioactivity on the filter was counted by liquid scintillation
spectroscopy. DK102 cells lacking Ste2p were used as a nonspecific binding control for
the assays. Binding assays were repeated a minimum of 3 times, and similar results were
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observed for each replicate. Specific binding for each mutant receptor was calculated by
subtracting the nonspecific values from those obtained for total binding. Specific binding
data were analyzed by nonlinear regression analysis for single-site binding using Prism
software (GraphPad Software, San Diego, CA) to determine the Km (in nanomolars) and
Bmax values (receptors/cell) for each mutant receptor.

Matrix-Assisted Laser Desorption Ionization−Time of Flight (MALDI−TOF)
BJS21 cells expressing either the WT or G188TAG Ste2p were grown in the
presence or absence of Bpa and used to prepare total cell membranes as previously
described (20). Approximately 3 mg of cell membranes was resuspended in ice-cold
solubilization buffer [50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1 mM
ethylenediaminetetraacetic acid (EDTA), and 1% Triton X-100] with protease inhibitors
(PMSF, pepstatin A, and leupeptin), incubated overnight at 4°C with end-over-end
mixing, and then centrifuged at 15000g for 30 min to remove nonsoluble material. The
solubilized proteins were then mixed with FLAG resin (Sigma/Aldrich Chemical Co., St.
Louis, MO) and incubated at 4°C with end-over-end mixing for 6 h. The resin was
collected by centrifugation at low speed (800g for 1 min) and resuspended and collected
4 times in TBS buffer (25 mM Tris-HCl, 140 mM NaCl, and 3 mM KCl at pH 7.4). Ste2p
was eluted by resuspending the resin in 1 mL of ice-cold elution buffer (0.1 M glycine
HCl at pH 3.5) and incubated at 4°C with end-over-end mixing for 5 min. The resin was
pelleted by centrifugation (2000g for 1 min), and the supernatant, containing the eluted
Ste2p, was transferred to a fresh tube containing 20 µL of 0.5 M Tris-HCl at pH 7.4 and
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1.5 M NaCl. Purity and concentration of samples was estimated by Coomassie Blue and
silver staining of SDS−PAGE gels. The samples were also analyzed by immunoblotting
using an antibody to the FLAG epitope on the C terminus of Ste2p.
Samples containing eluted Ste2p (50 µg) were dried by vacuum centrifugation
(Thermo Scientific, Waltham, MA) and then dissolved in 100% trifluoroacetic acid
(TFA) containing 10 mg/mL cyanogen bromide (CNBr). Deionized−distilled water
(ddH2O) was then added to adjust the final TFA concentration to 70%, and the sample
was incubated at 37°C in the dark for 18 h. The samples were dried by vacuum
centrifugation and washed 3 times with ddH2O and resuspended in 0.1% TFA. The
resulting CNBr peptide fragments were further washed and concentrated using ZipTip
pipet tips (Millipore Corporation, Billerica, MA) following the directions of the
manufacturer and resuspended in 70% acetonitrile/30% water (0.1% TFA). For
MALDI−TOF analysis, α-cyano-4-hydroxy-trans-cinnamic acid (ACHA, Sigma/Aldrich
Chemical Co., St. Louis, MO) at a concentration of 20 mg/mL in 50% acetonitrile/50%
water (0.1% TFA) was used as the matrix. The digested samples (0.5 µL eluate from
ZipTip) were either mixed with 0.5 µL of matrix before spotting on the target or 1.0 µL
of matrix was spotted and allowed to dry before applying 1.0 µL of samples.
MADLI−TOF spectra were acquired on a Bruker Daltonics (Boston, MA) Microflex
using both reflector and linear methods.
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Crosslinking
A biotinylated form of α factor, [K7(biotinylamidocaproate), Nle12]α factor, was
prepared as previously described (27). Membranes prepared from BJS21 cells expressing
the F55TAG, G188TAG, and Y193TAG receptors, grown at room temperature in the presence
or absence of Bpa (1 mM), were suspended in PPBi buffer [0.5 M potassium phosphate at
pH 6.2, 10 mM tert-amyl methyl ether (TAME), 10 mM sodium azide, 10 mM potassium
fluoride, and 0.1% bovine serum albumin (BSA)], incubated with biotinylated
pheromone (1 µM) in the presence or absence of nonbiotinylated pheromone (100 µM)
for 30 min at room temperature, and then chilled to 4°C for the remainder of the
procedure. Cross-linking was performed as previously described (27). Briefly, the
membranes were exposed to UV light at 365 nm using a Stratalinker (Stratagene, La
Jolla, CA) for three 15 min intervals. The cross-linked membranes were washed 3 times
with CAPS buffer [10 mM N-cyclohexyl-3-aminopropanesulfonic acid (Sigma, St. Louis,
MO) at pH 10] by centrifugation to remove noncross-linked biotinylated α factor,
fractionated by SDS−PAGE and immunoblotted with antibody to Ste2p and with
Neutravidin−horseradish peroxidase (HRP) conjugate (Pierce, Rockford, IL) to detect the
biotinylated pheromone covalently linked to the receptor. The signal generated by the
Neutravidin−HRP conjugate associated with the biotinylated ligand−receptor complex
was quantitated by measurement of the band density using Quantity One software
(version 4.5.1) on a Chemi-Doc XRS photodocumentation system (BioRad, Hercules,
CA). Before fractionation by SDS−PAGE, the amount of protein in each sample was
determined, and amounts specified in the text were loaded into each lane.
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Chapter 3
Results
Effect of Bpa Incorporation on Ste2p Expression and Signal Transduction
The amber stop codon TAG was inserted into the STE2 coding sequence by sitedirected mutagenesis at the eight sites indicated in Figure 2.1. On the basis of the latest
information concerning Ste2p topology (28-30), the sites were located in the first
transmembrane domain (F55TAG), in the first (S107TAG, G115TAG, and V127TAG) and
second (Y193TAG and F204TAG) extracellular loops, at the border between the fourth
transmembrane domain and the second loop (G188TAG) and in the sixth transmembrane
domain (Y266TAG). These residues were selected on the basis of several criteria: (i)
location, either in an extracellular loop or near the interface between a TM and an
extracellullar surface, (ii) prior site-directed mutagenesis studies indicating that the
residues (S107, G115, V127, and G188) were tolerant to amino acid substitution (31),
and (iii) conservation of the aromatic functional group (F55, F204, and Y266) (32, 33).
The plasmids bearing these mutations and the plasmid pECTyrRS/tRNACUA, which
encoded the tRNA/tRNA synthetase pair, were transformed into DK102 and BJS21 cells.
Cell membranes isolated from strain BJS21 expressing the TAG mutant constructs and
the tRNA/tRNA synthetase pair were immunoblotted and probed with antibodies directed
against the C-terminal FLAG epitope tag and the N-terminal 100 amino acids of Ste2p
(26) to determine the effect of the amber stop codon on protein synthesis in the presence
and absence of Bpa.
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Figure 2.1 Sites targeted for Bpa insertion into Ste2p. The coding region of the STE2
gene was modified to introduce the amber TAG codon, resulting in the insertion of Bpa
into Ste2p at the sites indicated in black (F55, S107, G115, V127, G188, Y193, F204, and
Y266). The FLAG and His tags are underlined.

To determine if the Ste2p−Bpa mutant proteins were able to bind ligand and
ultimately transduce the signal across the cell membrane, growth arrest or “halo” assays
were conducted on these transformed cells. Disks impregnated with α factor were placed
onto a top agar lawn of DK102 cells putatively expressing Ste2p−Bpa receptors, and the
plates were incubated at room temperature for 48−72 h. The rationale to conduct these
studies was 2-fold. In the absence of Bpa, the tRNA should not be charged, resulting in
the production of truncated Ste2p. In this case, the cells should not respond to pheromone
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and growth arrest should not occur. In the presence of Bpa, the TAG codon should be
suppressed by the charged tRNA and full-length protein should be synthesized. If the
incorporation of Bpa results in expression, the mutant Ste2p proteins might bind
pheromone, resulting in the initiation of signal transduction ultimately resulting in growth
arrest, indicated by the formation of a clear halo around the disk.

Figure 2.2 Halo assays of WT and Bpa mutant receptors. Cells lacking receptor (A
and B), cells containing WT Ste2p (C and D), or cells with mutated Ste2p (E−T) were
plated onto medium in the presence and absence of Bpa. Disks containing α factor (2, 1,
0.5, 0.2, and 0.1 µg/disk, starting at the 12 O’clock position on each plate and moving
counter-clockwise) were placed onto the lawn of cells. The plates were incubated for
48−72 h at room temperature.
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For cells expressing WT Ste2p, dose-dependent halos with well-defined borders
and clear zones of inhibition were formed in both the presence and absence of Bpa,
indicating that Bpa addition to growth medium did not affect the pheromone response
(parts C and D of Figure 2.2). Full-length WT Ste2p was synthesized in both the presence
and absence of Bpa and could be detected by both N-terminal (Figure 2.3A) and Cterminal (Figure 2.3B) antibodies. Cells that were deleted for Ste2p did not form halos in
either the presence or absence of Bpa (parts A and B of Figure 2.2), and Ste2p was not
detected on immunoblots (Figure 2.4).
The mutants F55TAG (Figure 2.2E) and F204TAG (Figure 2.2Q) formed dosedependent halos in the absence of Bpa, although these halos were “fuzzy”, referring to
the poor definition of the borders and reduced clarity of the zone of inhibition compared
to the WT control. The fuzzy nature of these halos is most likely due to a decreased
receptor number or to more rapid desensitization of the Bpa mutant receptor, resulting in
a recovery from the growth arrest response (34, 35). Immunoblot analysis indicated that,
in the absence of Bpa, the protein expression level of the F55TAG mutant was below the
limit of detection (Figure 2.3A) and the expression of the F204TAG mutant was very low
(Figure 2.4). Despite the inability to visualize the F55TAG protein on the immunoblot,
sufficient protein was made by read-through expression to produce the biological
response and to be detected by the ligand binding assay (see below). The observation that
low levels of Ste2p are sufficient to result in signal transduction was made previously
(36). These investigators reported that only a fraction of the receptors in a normal cell are
necessary for signaling and that reduction of the receptor level to below 5% of the normal
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level led to smaller, turbid, fuzzy-edged growth arrest zones in response to α factor. The
lack of receptor expression was required to completely block α-factor-induced growth
arrest.

Figure 2.3 Immunoblots of membranes isolated from cells expressing Bpa mutant
Ste2p. In each panel, the arrow at the left indicates the band corresponding to full-length
Ste2p. (A) C-Terminal FLAG and (B) N-terminal anti-Ste2p immunoblots prepared from
cells expressing the F55, G188, and Y193 receptors grown in the presence and absence of
2 mM Bpa. In B, the arrows in the lower portion of the figure indicate truncated forms of
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Ste2p. (C) FLAG immunoblot of membranes prepared from cells expressing the F55TAG
receptor in the presence of increasing concentrations of Bpa.

Figure 2.4 Immunoblots of membranes isolated from cells expressing Ste2p mutants
with the TAG codon inserted at specific residues indicated in the figure. The arrow at
the left indicates the band corresponding to full length Ste2p. The receptors were detected
with an antibody to the C-terminal FLAG epitope. Membranes were prepared from cells
grown in the presence (+) and absence (-) of 2 mM Bpa as indicated in the figure.

The presence of halos for the F55TAG and F204TAG receptors in the absence of Bpa
indicates that there was “read-through” of the amber stop codon (allows translation to
read through the amber stop codon and produces full-length protein), resulting in the
production of a functional receptor. In contrast, in the presence of Bpa, these same
mutants did not form halos (parts F and R of Figure 2.2). Subsequent immunoblot
analysis indicated that the expression of the F55TAG (Figure 2.3A) and F204TAG receptors
was enhanced in cells grown in the presence of Bpa (Figure 2.4), suggesting that Bpa was
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incorporated into Ste2p but was not tolerated at those positions, resulting in nonsignaling
receptors. The expression was at relatively low levels; 15 times more protein was loaded
for the mutants to allow for detection by the immunoblot compared to that of the WT (30
versus 2 µg).
Receptors with mutations at positions S107 (Figure 2.2G), G115 (Figure 2.2I),
and V127 (Figure 2.2 K) also exhibited read-through expression. Halos formed in the
absence of Bpa, although they were fuzzy for the G115TAG and V127TAG receptors. Little
or no protein was detected by immunoblot analysis for these three receptors when cells
were grown in the absence of Bpa (Figure 2.4) indicating again, as in the case of F55TAG,
expression was below the limit of detection for the immunoblot even though sufficient
protein was made by read-through expression to produce the biological response. In the
presence of Bpa, expression of these three mutants resulted in halo formation, although
the halos were not well-delineated (parts H, J, and L of Figure 2.2, respectively).
Immunoblot analysis indicated that expression of these three proteins was enhanced in
cells grown in the presence of Bpa (Figure 2.4). Thus, the decline in halo definition,
despite the fact that there was an increase in Ste2p protein, indicates that Bpa was
incorporated into these receptors but the function was compromised.
For the mutant at position Y193, no halos were formed in the absence of Bpa,
suggesting that no functional Ste2p was expressed (Figure 2.2O), although a low-level
full-length protein was detected by immunoblot analysis with the C-terminal antibody
(Figure 2.3A). In contrast, in the presence of Bpa, dose-dependent fuzzy halos were
formed, indicating that Bpa was inserted in response to the TAG codon, resulting in a
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functional protein (Figure 2.2P). In parallel with this increase in Ste2p function, there was
a concomitant increase in protein expression (Figure 2.3A) for cells grown in the
presence of Bpa. The G188TAG mutant had a similar phenotype (parts M and N of
Figure 2.2) but with less defined halos observed only at the highest amount of pheromone
and only in the presence of Bpa. The poor definition of the halos suggested that Bpa was
not well-tolerated at this position. For the G188 receptor, there was no detectable protein
produced in the absence of Bpa and a weak but clearly discernible band was detected in
membranes obtained from cells grown in the presence of Bpa (Figure 2.3A). Finally, the
Y266TAG receptor was not functional in either the presence or absence of Bpa (parts S and
T of Figure 2.2), and immunoblot analysis (Figure 2.4) indicated that this receptor was
not expressed under either condition.
C-Terminally truncated forms of the receptor can be seen for the G188TAG and
Y193TAG receptors using antibody to the N terminus (Figure 2.3B). Three major bands
were detected at 23, 21, and 18 kDa for the G188TAG and at 24, 22, and 19 kDa for the
Y193TAG receptor. These bands corresponded to the expected size of the nonglycosylated
receptor and its two major glycosylated states truncated at the inserted stop codons (37).
The origin of the bands of higher molecular weight (between 22 and 50 kDa) in the
G188TAG and Y193TAG lanes (Figure 2.3B) was not investigated, although these bands are
not related to the absence or presence of Bpa. Truncated forms of the F55TAG receptor
were not detected with the N-terminal antibody (Figure 2.3B) on this immunoblot
because the predicted receptor fragment (6 kDa) would not have been retained on the gel.
Note that the full-length Ste2p band intensity (52 kDa) for the WT strain is less intense as
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detected by the N-terminal antibody (Figure 2.3B) than that of the same membranes
probed with the FLAG antibody (Figure 2.3A). In our hands, the FLAG antibody always
yields a stronger signal than the N-terminal antibody. This provides an explanation for
the observation that, although full-length Bpa-containing proteins can be detected with
the FLAG antibody, they are barely discernible by the N-terminal antibody. Expression
of the full-length F55TAG Bpa-containing receptor was enhanced in response to an
increased Bpa concentration in the growth medium (Figure 2.3C). At a low concentration
(0.2 mM Bpa), no increase over control (no Bpa) was observed, while at higher
concentrations (2 mM), the signal corresponding to Ste2p on the immunoblot was
enhanced, increasing by 2.6-fold over the control as measured by band intensity. Similar
results were obtained for the G188TAG and Y193TAG mutants (data not shown), suggesting
that entry of Bpa into the cell is one factor determining the efficiency of Bpa insertion
into the protein.

Effect of Bpa-Containing Peptides on the Expression of Ste2p
The data for the F55TAG, G188

TAG

, and Y193

TAG

receptors described above

suggests that the expression of Bpa-containing Ste2p could be enhanced if Bpa were
more efficiently delivered into the cell. It is known that small peptides enter yeast cells
intact through the di/tripeptide transporter Ptr2p (38, 39), and upon entry into the cell,
these peptides are hydrolyzed to free amino acids. In an attempt to increase the delivery
of Bpa into the cell, a Bpa-containing dipeptide (Met−Bpa) was synthesized. Methionyl
di- and tripeptides are excellent substrates for the yeast peptide transport system (40).
40

Cells expressing the F55TAG, G188TAG, and Y193TAG receptor constructs were grown in
the presence and absence of Met−Bpa, and membranes were isolated and probed with the
C-terminal FLAG antibody to detect full-length protein. The expression of full-length
WT Ste2p was not affected by the presence of Met−Bpa, confirming that this compound
did not interfere with normal Ste2p expression at the concentrations indicated (Figure
2.5A). The Y193TAG mutant expressed minimal FLAG-reactive Ste2p in the absence of
Bpa, but in the presence of Met−Bpa (Figure 2.5B), full-length protein was detected.

Figure 2.5 Use of a peptidyl form of Bpa. FLAG immunoblot analysis of membranes
from cells expressing either WT (A) or Y193TAG (B) Ste2p receptors grown in the
presence of the dipeptide Met−Bpa or free Bpa at the concentrations indicated. Protein
loads were 2 and 30 µg for the WT and Y193 mutant, respectively.

In comparison to the expression of Y193TAG grown in the presence of 0.1 mM
Met−Bpa to that grown in the presence of 0.1 mM Bpa (Figure 2.5B), expression was
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greater for the dipeptide (3.1-fold increase). At higher concentrations (0.5 and 2 mM),
growth on Met−Bpa and Bpa yielded similar levels of expression (1.4-fold increase at
each concentration). Similar results were obtained for the F55TAG and Y193TAG mutants.
Growth on dipeptide at 0.1 mM resulted in 2.4- and 2.0-fold increases in expression
compared to growth on 0.1 mM Bpa for the F55TAG and Y193TAG mutants, respectively.
At higher concentrations of peptide (0.5 mM and 2 mM), growth on Met−Bpa did not
increase Ste2p expression when compared to the same concentration of Bpa.

Cell-Surface Expression of Bpa Mutants Determined by Saturation Binding Assay
To characterize the cell-surface expression and binding affinity of the Ste2p Bpa
mutants, DK102 cells expressing the F55TAG, G188TAG, and Y193TAG receptors were used
in whole-cell binding assays. Binding of radiolabeled α factor was detected for cells
expressing the WT receptor when cultured in either the presence or absence of Bpa. In
experiments using the WT receptor, Bpa did not have any significant effect on the Bmax
and binding affinity (Bmax = 152,470 ± 6900 receptors per cell, Kd = 9.7 ± 1.4 nM) when
compared to cells cultured in the absence of Bpa (Bmax = 158,100 ± 6500 receptors per
cell, Kd = 11.0 ± 1.0 nM). For the mutant receptors, binding was not detected for cells
grown in the absence of Bpa (data not shown). However, for cells grown in the presence
of Bpa, saturable binding was observed (Figure 2.6). The Bmax values for the mutants
were reduced by 10−20-fold compared to the WT receptor (Figure 2.5), which is
consistent with the low level of expression observed in the immunoblots (Figure 2.3).
The binding affinity (Kd) of the Y193TAG and G188TAG mutants (12.8 ± 4.9 and 17.5 ± 5.7
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nM, respectively) were similar to that for the WT receptor, indicating that substitution of
Bpa for the endogenous amino acid at these positions did not affect the interaction of the
ligand with the receptor. In contrast, for the F55TAG mutant, the binding affinity was
reduced to 78.9 ± 46.1 nM, indicating that the substitution of Bpa for phenylalanine at
this position affected ligand binding, which correlates to the relative low signaling
activity of this receptor.

Figure 2.6 Whole cell saturation binding assay of [3H]α factor to WT Ste2p and
Ste2p−TAG mutant receptors. Cells expressing the WT receptor and the indicated Bpa
mutants were grown in the presence of 2 mM Bpa. (Inset) Saturation binding assay for
TAG mutant receptors plotted on an expanded scale. The data represent specific binding
to cells as determined by subtracting the binding to an isogenic strain lacking the receptor
from binding to cells containing WT or mutant Ste2p.
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MALDI−TOF Indicates that Bpa Is Incorporated into Ste2p at Position G188
To confirm the incorporation of Bpa into Ste2p, MALDI−TOF mass
spectrometric analysis of purified WT and G188TAG receptors was performed. The
G188TAG receptor was chosen for this analysis based on nearby naturally occurring
methionine sites in Ste2p that would yield a small peptide (residues 181−189) upon
CNBr cleavage to facilitate mass spectroscopy. The substitution of glycine (75.07 Da) for
Bpa (269.30 Da) at position 188 should result in a mass shift of 194 Da in the 188Bpacontaining peptide. To estimate purity and concentration of the samples prior to CNBr
cleavage and MALDI−TOF analysis, Coomassie Blue and silver staining of SDS−PAGE
gels was performed on the purified G188TAG and WT receptors. In the Coomassie-stained
gel, only two bands, corresponding in molecular weight to the glycosylated and
nonglycosylated forms of Ste2p (50−52 kDa), were observed. Using the more sensitive
silver-staining technique on the same sample, the same two bands were detected, along
with some very faint bands not corresponding to Ste2p. Immunoblot analysis confirmed
that the two major bands were Ste2p (data not shown). After CNBr cleavage of WT and
G188TAG receptors, we carried out a MALDI−TOF analysis of the peptide fragments
generated, focusing on the molecular-weight region corresponding to the peptide with the
putative Gly to Bpa substitution. Our analysis of the CNBr-cleaved WT and G188TAG
receptors (Figure 2.7) revealed a mass shift from 954.154 Da in WT to 1146.46 Da in
G188TAG, corresponding to a 192 Da increase. Other peaks of identical mass
corresponding to CNBr fragments of Ste2p were observed in both the WT (1473.81 and
1505.39 Da) and G188Bpa (1474.45 and 1506.19 Da) receptors. Some peaks not
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corresponding to any of the theoretical masses of Ste2p CNBr fragments were also
observed and are likely due to the degradation of Ste2p, which occurred during the
overnight incubation at 37°C during CNBr cleavage, or the presence of other peptides in
the preparation.

Figure 2.7 MALDI−TOF analysis of CNBr cleavage fragments of WT and G188TAG
receptors. A peak (954.15 Da) corresponding to residues 181−189 (YFVSAVKGM) in
the WT receptor was not present in the G188TAG receptor. The masses for the CNBr
fragments indicated that the carboxyl-terminal methionine is converted to homoserine
lactone. A new peak (1146.46 Da) corresponding to 181−189 with Bpa at position 188
was detected. Other peaks corresponding to residues 55−69 and 166−180 were observed
for both WT and G188TAG receptors.
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Bpa at Positions F55 and Y193 Can Cross-link to the α-Factor Ligand
To determine if Bpa incorporated into Ste2p could be used to cross-link to and
thus capture the α-pheromone, cells expressing the WT, F55TAG, G188TAG, and Y193TAG
receptors as well as cells lacking Ste2p as a control were grown in the presence of Bpa.
Membranes were prepared and incubated with or without [K7(biotinylamidocaproate)]α
factor, an α factor analogue that contains biotin on the position seven lysine of the
pheromone and binds to the receptor with high affinity (27). Cross-linking was also
evaluated in the presence or absence of 100-fold excess nonbiotinylated α factor. After
incubation, the membranes were exposed to UV light to activate capture of pheromone to
the Bpa-labeled receptor. The membranes were fractionated by SDS−PAGE, blotted, and
then probed with FLAG antibody to detect Ste2p (Figure 2.8A) or Neutravidin−HRP to
detect biotinylated ligand (Figure 2.8B). WT receptor was expressed at levels higher than
any of the mutant receptors (Figure 2.7A) as seen in previous experiments (Figure 2.3).
When the immunoblots were probed with Neutravidin−HRP (Figure 2.8B), a distinct
band was detected at the size expected for Ste2p in the F55TAG and Y193TAG receptors,
indicating that the biotinylated α factor was cross-linked. Despite the fact that at least 20
times as much WT Ste2p was expressed when compared to the F55TAG or Y193TAG
receptors (Figure 2.8A), covalent labeling as detected with Neutravidin−HRP was
significantly stronger for the mutants (Figure 2.8B). Moreover, labeling of the F55TAG
and Y193TAG Bpa-containing receptors was reduced in the presence of excess
nonbiotinylated α factor (Figure 2.8B) by 83 and 64%, respectively, as determined by
quantitation of the band density. Similar results were observed in three independent
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replicates of this experiment. For membranes prepared from cells lacking the receptor, as
well as for the WT and the G188TAG receptors, a faint band at approximately 50 kDa was
observed (Figure 2.8B) that was dependent upon incubation of the membranes with
biotinylated pheromone. The signal was not affected by the presence of nonbiotinylated
pheromone. Thus, this signal is the result of nonspecific association of the biotinylated
pheromone with the membranes in a Ste2p-independent manner.

Figure 2.8 Cross-linking of biotinylated α factor into Bpa-containing receptors.
Membranes prepared from cells expressing the WT, F55TAG, G188TAG, and Y193TAG
receptors grown in the presence of Bpa were incubated with [K7(biotinylamidocaproate),
Nle12]α factor (1 µM) in the presence (+) or absence (−) of nonbiotinylated α factor (100
µM). Membranes were also prepared from cells lacking the receptor as a negative
control. (A) After photoactivation, membranes (2 µg for WT and 25 µg for mutants and
the negative control) were immublotted and probed with FLAG antibody to detect Ste2p.
(B) Membranes (25 µg for each lane) were immunoblotted and probed with
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Neutravidin−HRP to detect biotinylated ligand. The arrow in both panels indicates the
expected size for Ste2p.
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Chapter 4
Discussion
Many experiments have been performed with a variety of methodologies to
provide a wealth of knowledge concerning GPCR structure and function. However, an
understanding of the mechanism of activation is still in its infancy. The gold standard
would be to obtain crystal structures of the GPCR in both the resting and active state.
Thus far, bovine rhodopsin and the human β-adrenergic receptor are the only GPCRs to
have had their crystal structure solved (41-43). For rhodopsin, the receptor was
crystallized in the inactive state, although recent reports of an active-state crystal at
moderate to low resolution (2.7−5.5 Å) have been published (44). Crystallization of the
β-adrenergic receptor required expression as a fusion protein (43) or interaction with an
inverse agonist (42) to stabilize receptor conformation. The use of unnatural amino acid
replacement provides an alternate method for examining the receptor structure as well as
exploring the changes that occur in GPCRs upon receptor activation.
In an earlier study, a fluorescent amino acid was incorporated into a GPCR, the
neurokinin-2 receptor, using heterologous expression in Xenopus oocytes (12). In this
paper, we report the first evidence that an unnatural amino acid can be incorporated into
the GPCR Ste2p expressed in its native environment in the yeast cell and still retain
function. The incorporation was verified by mass spectrometry, and our studies indicate
that, once incorporated, the photoactivatable Bpa in Ste2p can be used to covalently link
the α-factor ligand to the receptor. Although there are many examples in the literature of
photoactivated cross-linking of ligand to receptor, in all of those cases, the ligand
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contained the photoactivatable moiety. To our knowledge, our study represents the first
example of cross-linking of ligand to a GPCR in which the receptor contained the
photoactivatable group used to “capture” the ligand.
We demonstrated that incorporation of Bpa into both the F55 (located in TM1)
and Y193 (located in EL2) receptors resulted in capture of biotinylated pheromone.
Photochemical capture of the ligand could be largely inhibited by the presence of excess
nonbiotinylated pheromone. While F55 is positioned in the binding pocket of the receptor
and was expected to interact with the pheromone (27), the ability of Y193 to capture the
ligand suggests a possible role for EL2 in ligand binding. Previous studies using domain
swapping indicated that EL2 was not a determinant of ligand specificity of the S.
cerevisiae and S. kluyveri α-factor receptors (45). Thus, our observation of a putative
contact between the EL2 region of Ste2p and α factor indicates the need for further study
of EL2−α-factor interactions. Because of the low level of protein expression, it was
unclear whether the G188 receptor was functional with respect to ligand capture, despite
the fact that this receptor was determined to contain Bpa by mass spectrometry analysis
(Figure 2.7). Saturation binding analysis (Figure 2.6) indicated that the G188TAG receptor
was expressed on the cell surface at levels comparable to that of the F55TAG receptor, in
which we were able to detect cross-linking of the receptor to the pheromone. In this light,
despite the low level of total protein expression observed on the immunoblot, it is likely
that there is enough of the G188TAG receptor on the cell surface to allow for cross-linking
if the pheromone has access to the Bpa residue. Previously published data using cysteine
scanning of Ste2p indicated that G188 is between 25 and 50% exposed on the basis of the
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reaction with sulfhydryl reagents (46); thus, it is accessible to the solvent. If the
pheromone was interacting nonspecifically with the receptor or if residue G188 was
involved in ligand binding, then Bpa at this position should have been able to capture
ligand.
In addition to ligand capture experiments, we can envision other applications of
this mutagenesis methodology, such as studying changes in domain−domain interactions
upon ligand binding, which will shed light on the receptor activation mechanism. An
advantage of using the orthologous tRNA/aminoacyl-tRNA synthetase pair to incorporate
Bpa into Ste2p in the yeast cell is that the GPCR remains in its native environment and is
thus able to interact with downstream effector molecules, such as the heterotrimeric Gproteins, thus making assessment of both ligand binding and signal transduction possible.
Although the use of unnatural amino acids has the potential to answer very
important questions in GPCR biology, there are still obstacles to overcome. In the
experiments presented in this paper, eight mutant STE2 constructs (F55TAG, S107TAG,
G115TAG, V127TAG, G188TAG, Y193TAG, F204TAG, and Y266TAG) were created with the
amber TAG stop codon engineered at different sites within the open-reading frame.
Theoretically, when the cells expressing these mutant receptors were grown in the
presence of Bpa, the unnatural amino acid would be incorporated into the protein by the
cognate tRNA/aminoacyl-tRNA synthetase also expressed in the cell. In the absence of
Bpa, it was expected that the TAG codon would result in termination of protein synthesis,
resulting in a truncated protein. For the mutants G188TAG and Y193TAG, this was the case;
in the presence of Bpa, cells responded to pheromone (Figure 2.2) and full-length
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receptor was detected by immunoblot analysis (Figure 2.3, 2.4) and both bound ligand
(Figure 2.6) with near WT affinity. However, mutants with TAG amber stops at positions
F55, S107, G115, V127, and F204 exhibited variable amounts of inefficient stop codon
recognition or read-through expression, as evidence by the halo assay, which in the
context of the present experiments results in the production of full-length protein even in
the absence of Bpa.
The efficiency with which nonsense codons, such as the UAG amber stop in
mRNA, are suppressed can be affected by the context of the adjacent codons and poses a
challenge (47). In S. cerevisiae, nucleotides within six bases flanking the stop codon can
influence the efficiency of termination (48) and it has been determined that “backup” or
tandem stop codons can be found three codons downstream of the authentic stop for some
genes (49). In the case of read-through expression, noncognate tRNA species can misread
the stop codon and insert an inappropriate amino acid. In the case of the UAG codon in
yeast mRNA, the tRNAGln can insert glutamine at the stop codon when it is present in a
context unfavorable for release-factor recognition (50). In another tRNA/aminoacyltRNA synthetase system evolved to incorporate the fluorescent amino acid dansyl-alanine
in response to the amber stop codon, read-through expression in the absence of dansylalanine was eliminated by mutation of the aminoacyl-tRNA synthetase to increase
selectivity of the enzyme for dansyl-alanine (18). Thus, to optimize the system for
insertion of Bpa into Ste2p, genetic manipulations in protein translation machinery (i.e.,
ribosomes, tRNAs, etc.) might be warranted.
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Interestingly, for the mutants F55TAG and F204TAG, protein function but not
expression was eliminated when the cells were grown in the presence of Bpa (Figures
2.2, 2.3, 2.4). This indicates that the unnatural amino acid was incorporated into the
protein but did not result in a signal-transducing receptor at the cell surface. The presence
of mutant Ste2p or other GPCRs that are expressed and bind ligand but do not signal has
been extensively reported (3). Indeed, binding without signaling is characteristic of
antagonists, and mutation of GPCRs to preferentially recognize antagonists has been
documented (32, 33).
Incorporation of Bpa into the various TAG mutant receptors was not 100%
efficient, as can be seen by the presence of truncated receptors on immunoblots (Figure
2.3B), which could potentially interfere with the function of a full-length receptor.
However, previous studies showed that overexpression of 14 different truncated Ste2p
receptors failed to produce any significant alteration in Ste2p function (51). Thus, the loss
of signaling function (F55TAG and F204TAG) in the halo assays that we observed likely
results from intolerance of Bpa at the positions into which it was inserted rather than to
the interference by truncated receptors.
Using the orthologous tRNA/aminoacyl-tRNA synthetase pairs to incorporate Bpa
at the engineered amber stop codon requires the presence of Bpa in the cytoplasm at
sufficient concentrations to allow for effective charging of the tRNA. We have used a
novel means to supply Bpa to yeast cells via the di/tripeptide transport system that is
common to many eukaryotes (52, 53). In yeast, di/tripeptides as well as oligopeptides
(tetra/pentapeptides) are not cleaved outside the cell but are transported intact across the
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plasma membrane (54). Expression of the Y193TAG receptor as well as the F55TAG and
G188TAG receptors was noticeably greater when the cells were grown in the presence of
Met−Bpa at 0.1 mM when compared to Bpa (Figure 2.5). Because peptide transporters
are ubiquitous in living cells (53), this method might be used to enhance the delivery of
unnatural amino acids and extend this approach to amino acids that cannot enter cells
through amino acid permeases.
In summary, in this paper, we provide evidence that the unnatural
photoactivatable amino acid p-benzoyl-l-phenylalanine can be incorporated into a GPCR
in its native cell. The Y193TAG mutant receptor responded to α factor and bound this
ligand with nanomolar affinity. Other mutant receptors examined were expressed at the
membrane at levels from 5 to 10% of the WT receptor under identical conditions. Mass
spectrometry proved that Bpa was incorporated at the expected position for the G188TAG
receptor. Expression could be increased when the unnatural amino acid was delivered as
a dipeptide via the peptide transport system of S. cerevisiae. The enhancement of Bpa
delivery as a dipeptide was most effective at low (0.1−0.5 mM) concentrations; at 2 mM,
both dipeptide and Bpa were equally effective. Two Bpa-containing receptors were able
to capture ligand after photoactivation, providing evidence for the utility of such labeled
GPCRs to determine ligand−receptor interactions. These results set the stage for the use
of unnatural amino acids technology in exploring the structure and function of integral
membrane proteins in their native environment.
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PART III
Changes in Conformation at the Cytoplasmic Ends of the Fifth and
Sixth Transmembrane Helices of a Yeast G Protein-Coupled Receptor
in Response to Ligand Binding
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Abstract for Part III
The third intracellular loop (IL3) of G protein-coupled receptors (GPCRs) is an
important contact domain between GPCRs and their G proteins. Previously, the IL3 of
Ste2p, a Saccharomyces cerevisiae GPCR, was suggested to undergo a conformational
change upon activation as detected by differential protease susceptibility in the presence
and absence of ligand. In this study using disulfide cross-linking experiments we show
that the Ste2p cytoplasmic ends of helix 5 (TM5) and helix 6 (TM6) that flank the amino
and carboxyl sides of IL3 undergo conformational changes upon ligand binding, whereas
the center of the IL3 loop does not. Single Cys substitution of residues in the middle of
IL3 led to receptors that formed high levels of cross-linked Ste2p, whereas Cys
substitution at the interface of IL3 and the contiguous cytoplasmic ends of TM5 and TM6
resulted in minimal disulfide-mediated cross-linked receptor. The alternating pattern of
residues involved in cross-linking suggested the presence of a 310 helix in the middle of
IL3. Agonist (WHWLQLKPGQPNleY) induced Ste2p activation reduced cross-linking
mediated by Cys substitutions at the cytoplasmic ends of TM5 and TM6 but not by
residues in the middle of IL3. Thus, the cytoplasmic ends of TM5 and TM6 undergo
conformational change upon ligand binding. An α-factor antagonist (des-Trp, des-His-αfactor) did not influence disulfide-mediated Ste2p cross-linking, suggesting that the
interaction of the N-terminus of α-factor with Ste2p is critical for inducing
conformational changes at TM5 and TM6. We propose that the changes in conformation
revealed for residues at the ends of TM5 and TM6 are affected by the presence of G
protein but not G protein activation. This study provides new information about role of
66

specific residues of a GPCR in signal transduction and how peptide ligand binding
activates the receptor.
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Chapter 1
Introduction
G protein-coupled receptors (GPCRs) are integral membrane proteins that are
known to play important roles in cell communication by activating intracellular events
through both G protein-dependent and -independent processes (1-3). These receptors are
encoded by the largest gene family in mammals, constitute the main target of prescribed
drugs, and represent promising targets for new drug development (1, 3-6). They are
composed of seven transmembrane (TM) helical segments connected by intracellular and
extracellular loops. The core region of the receptor containing the seven TMs has been
found to be generally responsible for binding of small ligands, whereas peptide ligands
often bind to the extracellular portions as well as the core of GPCRs (7, 8). In the
classical model of ligand activation of a GPCR signal transduction pathway, the binding
of an agonist to the receptor induces conformational changes in the TMs propagated to
the cytoplasmic ends of a GPCR for G protein activation and transduction to various
intracellular metabolic events (1, 9).
The cytoplasmic surfaces of GPCRs contain multiple contact regions responsible
for receptor coupling to signal transduction complexes. The most prominent domains in
GPCRs for coupling are the second and third (IL3) intracellular loops as well as the Cterminal tail and TM boundaries (1-3). Comparing the crystal structure of opsin and
rhodopsin shows that the cytoplasmic end of TM6 is shifted outward from the center of
the bundle relative to its position in the inactive state (rhodopsin) and is closer to TM5 in
the active state (opsin) (10). Such movements have also been observed in other receptor
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such as M3 and adrenergic receptors using disulfide cross-linking of Cys mutant
receptors. In the M3 receptor, agonist binding increased the proximity between the
cytoplasmic ends of TM5 and TM6. Possible TM6 rotational movements were also
observed in the M3 receptor (11).
Several studies have shown that peptide ligands bind GPCRs and occupy a pocket
defined by side chains from extracellular loops and helices. The binding of the ligand
induces changes at the extracellular surface of the receptor resulting in conformational
changes at the cytoplasmic surfaces. These phenomena are believed to be critical for
GPCR activation (2). An explosion of recent crystal structures of ligand-bound
(activated) β1-adrenergic (12), β2-adrenergic (13), and A2a (14) receptors indicated major
changes in the cytoplasmic ends of TM5 and TM6 as a result of receptor activation.
Ste2p, the yeast Saccharomyces cerevisiae receptor for the pheromone α-factor, is
believed to have a structure similar to that of mammalian GPCRs. The third intracellular
loop of Ste2p has been shown to play an important role in signal transduction and is
involved in Gpa1p (the S. cerevisiae Gα protein) activation (15-18). Analysis of the Ste2p
IL3 demonstrated that IL3 becomes hypersensitive to proteolytic digestion with trypsin in
response to ligand binding, indicating that IL3 undergoes a conformational change that is
likely to be important for G protein activation(19), although specific residues that are
involved in these conformational changes were not identified. The TM5 and TM6 that
flank the IL3 have also been shown to interact with each other and have been suggested
to play a critical role in signaling (20). It is important to note that the Gα protein of the
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heteromeric G protein complex need not dissociate from Ste2p during receptor activation
as indicated by the full activity of a Ste2p-Gpa1p fusion chimera (21).
In this study, we have investigated IL3 and flanking TM5 and TM6
conformational changes by determining the propensity for disulfide cross-linking
between receptors carrying Cys substitutions. The IL3-Cys mutant receptors were
observed to form dimers with the pattern of dimer formation, suggesting the presence of a
310 helix in the middle of the IL3 loop. Addition of α-factor affected the levels of
disulfide formation in Cys-substituted receptors in portions of TM5 and TM6 contiguous
with IL3, implying that activation of Ste2p involved ligand-induced conformational
changes in the cytoplasmic ends of TM5 and TM6. In contrast, disulfide formation
involving residues in the middle of IL3 was not sensitive to ligand addition, indicating
that residues in the IL3 loop do not change conformation or availability during receptor
activation. The presence of an α-factor antagonist or a non-hydrolyzable GTP analogue
did not influence the levels of disulfide-mediated dimerization, suggesting that receptor
activation but not Gα activation was necessary for the observed conformational changes.
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Chapter 2
Material and Methods
Media, Reagents, and Strains and Transformation
Saccharomyces cerevisiae strain LM102 [MATa, bar1, leu2, trp1, ura3, FUS1lacZ::URA3, ste2Δ (22)] was used for Ste2p growth arrest and FUS1-lacZ assays. The
protease-deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52
ste2::KanR (23)] and TM5117 [MATa, bar1, leu2, his3, ura3, FUS1-lacZ::URA3, ste2Δ,
gpa1Δ (22)] were used for protein isolation and immunoblot analysis and disulfide crosslinking. Plasmids coding for the STE2 mutants and GPA1 mutants were transformed by
the method previously described (22) into LM102, TM5117, and BJS21 cells.
Transformants were selected by growth on minimal medium (24) lacking tryptophan
(designated as MLT) or lacking both tryptophan and uracil (designated as MLTU) to
maintain selection for the plasmids. All media components were obtained from BectonDickinson (Franklin Lakes, NJ).

Cysteine Scanning Mutagenesis
C-terminal FLAG and His-tagged STE2 with the two native cysteine residues
(Cys59 and Cys252) substituted with serine and cloned into the plasmid p424-GPD (high
copy plasmid) to yield plasmid pBEC2 (22) was used as the backbone for mutagenesis of
Ste2p. The plasmid pBEC2 was engineered by site-directed mutagenesis to individually
replace 30 residues in Ste2p (V224-Q253, see Figure 3.1) with cysteine as previously
described (22).
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Figure 3.1 Schematic diagram of Ste2p. Single cysteine at positions 224 to 253 (solid
circles) were introduced into the IL3 region of the STE2 gene. The FLAG and His tags
are underlined in the C-terminal tail.

Membrane Extraction and Immunoblots
BJS21 cells expressing STE2 and GPA1 constructs grown in their selective media
were used to prepare total cell membranes isolated as previously described (25). Cells
were harvested and lysed by agitation with glass beads in 700 μL of HEPES buffer (50
mM HEPES, 150 mM NaCl, pH 7.5) and the following concentrations of protease
inhibitors: 1.0 mM leupeptin,10 μM pepstatin A, and 5.0 mM phenylmethanesulfonyl
fluoride. The lysate was cleared by centrifugation at 3000g for 2 min. The membrane
fraction was harvested by centrifugation at 15000g for 30 min and was then resuspended
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in the HEPES buffer with 20% glycerol. Protein concentration was determined by
BioRad (BioRad, Hercules, CA) protein assay as previously described (22). For
immunoblot analyses the membrane extract was solubilized in SDS sample buffer
(BioRad, Hercules, CA), and 5 μg was fractioned by 10% SDS-PAGE. Blots were probed
with FLAG antibody (Sigma/Aldrich Chemical, St. Louis, MO) to detect Ste2p. The
signals generated were analyzed using Quantity One software (Version 4.5.1) on a
Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA). The student’s t
test was used to analyze differences in dimer formation (cross-linking) between
pheromone treated and nontreated receptors. A probability of p ≤ 0.01 was regarded as
statistically significant. Statistical analyses were performed with Prism (GraphPad
Software, San Diego, CA).

Growth Arrest Assays
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at
30°C in MLT, harvested by centrifugation, washed three times with water, and
resuspended at a final concentration of 5 × 106 cells/mL according to previously
described procedures (23). Cells (1 mL) were combined with 3.5 mL of agar noble
(1.1%) and poured as a top agar lawn onto MLT medium agar plates. Filter disks
(Whatman #1 paper) impregnated with α-factor pheromone (0.125–2.0 μg) were placed
on the top agar. The plates were incubated at 30°C for 18 h and then observed for clear
halos around the discs. The diameter of halos around the discs were measured, plotted as
diameter versus pheromone amount, and analyzed by linear regression analysis using
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Prism software (GraphPad Software, San Diego, CA) to determine the amount of
pheromone that yielded a 15 mm halo. The experiment was repeated at least three times,
and reported values represent the mean of these tests.

Fus1-lacZ Assays
LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants
were grown at 30°C in selective media, harvested, washed three times with fresh media,
and resuspended at a final concentration of 5 × 107 cells/mL. Cells (0.5 mL) were
combined with α-factor pheromone (final concentration of 1 μM) and incubated at 30°C
for 90 min. The cells were transferred to a 96-well flat-bottom plate in triplicates and
permeabilized with 0.5% Triton X-100 in 25 mM PIPES buffer, and then β-galactosidase
assays were carried out using fluorescein di-β-galactopyranoside (Molecular Probes, OR)
as a substrate (26). The reaction mixtures were incubated at 37°C for 60 min, and 1.0 M
Na2CO3 was added to stop the reaction. The fluorescence of the samples (excitation of
485 nm and emission of 530 nM) was determined using a 96-well plate reader Synergy2
(BioTek Instruments, Inc., Winooski, VT). The data were analyzed using Prism software
(GraphPad Software, San Diego, CA). The experiments were repeated at least three
times, and reported values represent the mean of these tests.

Saturation Binding Assay
Tritiated α-factor (9.3 Ci/mmol) was used in saturation binding assays on whole
cells. LM102 cells expressing Ste2p Cys-less as the wild-type and mutants with the Cys
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substitutions in IL3 (L228C, A229C, R233C, R234C, L248C, and I249C) were
harvested, washed three times with YM1 [yeast minimum medium with 0.5 M potassium
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium
fluoride, and 1% BSA], and adjusted to a final concentration of 4 × 107 cells/mL in
binding medium YM1i (YM1 plus protease inhibitors). Cells (630 μL) were combined
with 70 μL of 10X YM1i supplemented with [3H]α-factor and incubated at room
temperature for 30 min. The final concentration of [3H]α-factor ranged from 0.4× 10–9 to
50 × 10–9 M. Upon completion of the incubation interval, 200 μL aliquots of the cell–
pheromone mixture were collected in triplicate and washed over glass fiber filter mats
using the Standard Cell Harvester (Skatron Instruments, Sterling, VA). Retained
radioactivity on the filter was counted by liquid scintillation spectroscopy. LM102 cells
lacking Ste2p were used as a nonspecific binding control for the assays. Specific binding
for each mutant receptor was calculated by subtracting the nonspecific values from those
obtained for total binding. Specific binding data were analyzed by nonlinear regression
analysis for single-site binding using Prism software (GraphPad Software, San Diego,
CA) to determine the Kd (nM), and Bmax values (receptors/cell) for each mutant receptor
were calculated. The final values represent the binding constants from at least three
independent experiments.

Binding Competition Assays
This assay was performed using LM102 cells expressing C-terminal FLAG and
His-tagged Ste2p. Tritiated [3H]-α-factor (10.2 Ci/mmol, 12 μM) prepared as previously
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described (23, 27) was used in competition binding assays on whole cells. The cells were
grown at 30°C in MLT, harvested, washed three times with YM1 [0.5 M potassium
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium
fluoride, and 1% BSA], and adjusted to a final concentration of 2 × 107 cells/mL in YM1
plus protease inhibitors [YM1i (25)]. For the competition binding studies, cells (600 μL)
were combined with 150 μL of ice-cold 5X YM1i supplemented with 6nM [3H]α-factor
in the presence or absence α-factor or α-factor antagonist and incubated at room
temperature for 30 min. The final concentrations of α-factor and α-factor antagonist
varied from 0.5 × 10–10 to 1 × 10–6 M. After incubation, triplicate samples of 200 μL
aliquots were filtered and washed over glass fiber filter mats using the Standard Cell
Harvester (Skatron Instruments, Sterling, VA) and placed in scintillation vials. The
radioactivity [3H] on the filter was counted by liquid scintillation spectroscopy. The
binding data were analyzed by nonlinear regression analysis for one-site competition
binding using Prism software (GraphPad Software, San Diego, CA) (28). The final values
represent the binding constants from at least three independent experiments.

Disulfide Cross-Linking
Membrane proteins (in HEPES buffer, 20% glycerol) extracted from BJS21 cells
expressing Ste2p mutants coexpressed with wild-type Gpa1p were treated with CuP (1.0
μM Cu and 3.0 μM 1,10-phenanthroline) and incubated at room temperature for 30 min.
The reaction was quenched by addition of EDTA (ethylenediaminetetraacetic acid) and
NEM (N-ethylmaleimide) to final concentration of 10 mM. The cross-linked samples
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were resuspended in nonreducing SDS sample buffer (BioRad, Hercules, CA) and
resolved on 10% SDS-PAGE as described above. The disulfide reaction was reversed by
reducing with 4% 2-mercaptoethanol (β-ME) in the SDS sample buffer before resolving
it on SDS-PAGE. To investigate the effects of ligand or GTP-γ-S on cross-linking,
membrane fractions were incubated in HEPES buffer containing 5 μM α-factor
(WHWLQLKPGQPNleY) or 5 μM α-factor antagonist (desW,desH-α-factor =
WLQLKPGQPNleY) in the presence or absence of 0.1 mM GTP-γ-S1 before CuP
treatment.
For in vivo (whole cell) cross-linking, cells were grown to mid-log phase,
harvested, and washed with water by centrifugation (4000g for 5 min). The cells were
resuspended in 100 mM LiAc and incubated at 30°C for 30 min with mixing. After
centrifugation, the cells were resuspended in 25% PEG with 250 mM LiAc and incubated
for 60 min to make them permeable to CuP. Cells were washed with HEPES buffer three
times after LiAc treatment and then resuspended in YM1i buffer containing 5 μM αfactor or α-factor-antagonist and incubated at room temperature for 30 min. Disulfide
cross-linking was induced by adding CuP to final concentrations of 0.5 mM Cu and 1.5
mM 1,10-phenanthroline as previously described for yeast whole cell cross-linking (29).
The mixture was incubated at room temperature for 60 min with end-over-end mixing.
EDTA and NEM to final concentrations of 10 mM were added to stop the reaction. The
cells were washed three times with HEPES buffer containing EDTA (10 mM) and NEM
(10 mM). Membrane extraction was carried as described above with HEPES buffer
containing 10 mM EDTA/NEM. Reducing conditions of disulfide bond were carried out
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by resuspending membrane samples in SDS-PAGE sample buffer containing 4% β-ME
and incubating at room temperature for at least 15 min. To investigate the role of Gpa1p
in the TM5-IL3-TM6 conformational changes, disulfide cross-linking of Cysless, L228C
(TM5), L236 (IL3), and I249C (TM6) was carried out in a Gpa1p deleted strain, TM5117
as described above. For the time course experiments, the CuP-mediated disulfide crosslinking in BJS21 was terminated at the indicated time points by addition of EDTA and
NEM to final concentrations of 10 mM.

Prediction and Modeling
All models of 3-D structures were generated by the Phyre Structural Bioinformatics
Group prediction tools (30). The structures were viewed and labeled with the PyMOL
pdb viewer software (DeLano Scientific LLC, Palo Alto, CA).
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Chapter 3
Results
Phenotypes of Ste2p IL3 Cys Substitution Mutants
The signaling activities of the cysteine mutants were examined by α-factorinduced growth arrest and FUS1-lacZ induction assays. The growth arrest assay is a
sensitive test that measures the ability of cells expressing Ste2p to maintain pheromoneinduced cell division arrest at the G1 phase over a 24–36 h time frame, whereas the
FUS1-lacZ induction assay measures an early response of the yeast cell to pheromone.
The strains used in this study contain a reporter gene construct consisting of a fusion
between FUS1 promoter and the lacZ gene encoding the enzyme β-galactosidase (26).
This allows for rapid, sensitive detection of mating pathway activation by assessing βgalactosidase activity in response to mating pheromone.
The Cys-less Ste2p engineered as the background for the specific cysteine
mutations has been shown to have biological activities identical to the wild-type receptor
(22). In this study we grouped the IL3 residues into three categories based on their
position as follows: group 1 (TM5-IL3 boundary) residues, V224–S232; group 2 (middle
IL3) residues, R233–Q240; and group 3 (IL3-TM6 boundary) residues, F241–Q253
(Figure 3.1). Substitution of single cysteine residues in intracellular loop 3 (IL3) of Cysless Ste2p resulted in constructs that were expressed and had biological activities
identical or similar to that of the Cys-less receptor, except for K225C which was
biologically inactive (see Table 3.1). The decreased sensitivity in biological assays
caused by the K225C mutation has been observed in previous studies (31).
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Table 3.1 Summary of Phenotypes of Ste2p IL3 Cys Substitution Mutantsa

a

The expression levels as measured by Western blots (Figures 3.3 and 3.6) and biological

activities all had standard deviations between ±2 and ±5%. All assays were done at least
three times independently.
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Figure 3.2 Whole cell saturation binding assay of [3H]α-factor to Cysless and IL3
Cys mutant receptors. A graph of CPM (count per minute of radioactivity of cells)
versus the concentration of the [3H]α-factor is shown. The data represents specific
binding to cells as determined by subtracting the binding to cells lacking the receptor
from binding to cells containing the Ste2p Cys mutant receptors. Below the graph is a
table containing a summary of the binding affinities (Kd) and surface expression of the
receptors.
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Receptor expression was measured by Western blot signals that were quantitated
using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation
system (BioRad, Hercules, CA). The Cys-less receptor signal was used as the measure of
100% expression. In addition to quantitation of the Western blot signals, saturation
binding assays were carried out on selected mutants (L228C and A229C) from the TM5–
IL3 boundary, (R233C and R234C) from the middle of IL3, and (L248C and I249C) from
the IL3–TM6 boundary (Figure 3.2). The receptors showed almost equal Kd values for
ligand binding, and receptors L228C, A229C, L248C, and I249C were expressed at levels
within 12% of the Cys-less control, whereas R233C and R234C were expressed to about
55–63% of control, as judged by Bmax values.

IL3 Cys Mutants Form Dimers
One of the most commonly used strategies to investigate GPCR agonist-induced
conformational change is disulfide cross-linking involving cysteine-substituted mutant
GPCRs. This approach involves determination of differences in disulfide formation
between two receptor monomers containing Cys residues in the presence and absence of
ligand (29, 32, 33). Ste2p predominates in SDS-PAGE as a monomer of about 50 kDa as
noncovalent interactions between receptors are disrupted by the conditions of the SDSPAGE. As observed in many studies (8, 22), some SDS-resistant dimers persist in all
lanes including that of the Cys-less receptor (Figure 3.3). We observed strong dimer
formation in some of the IL3 Cys mutant receptors when treated with CuP. Compared to
the Cys-less receptor, which showed little or no increase in the dimer band at 100 kDa
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upon incubation of membranes with CuP, both the R233C and R234C receptors showed
marked increases in the dimer band. This increase was completely (R234C) or almost
completely (R233C) reversed by addition of β-ME, indicating the involvement of
disulfide bonds in stabilization of the dimer.

Figure 3.3 Ste2p IL3 Cys mutants form dimers. Membranes from various mutants
were incubated with or without CuP in the presence or absence of α-factor as described in
the Material and Methods. The membrane extracts were run on SDS-PAGE gels; the gels
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were blotted and probed with anti-FLAG antibody to detect the presence of Ste2p at
either the monomer (M) or dimer (D) positions. Each preparation was untreated (lanes −,
−) or treated with CuP (lanes −, +) or with α-factor and CuP (lanes +, +).

Given that the disulfide cross-linking was observed with Ste2p(R233C) and
Ste2p(R234C), a comprehensive examination of the cross-linking of Cys mutants in the
IL3 region of the receptor was conducted. These experiments were done in the presence
and absence of ligand in order to determine whether cross-linking changed during
activation of the receptor (Figure 3.3). Examination of the ratio of dimer to monomer in
the gels of all the IL3 Cys mutants showed that some mutants exhibited high levels of
disulfide formation [e.g., Ste2p(L236C), group 2; Figure 3.3)], whereas others exhibited
only a small increase in dimer content with the monomer remaining the predominant
species (e.g., L228C, group 1; Figure 3.3). When treated with CuP in the absence of
ligand, disulfide cross-linked receptor formation for the 22 single Cys mutants studied
varied from 10% to 96% of the total Ste2p related bands (monomer plus dimer) (Figure
3.3, compare lanes “– –”and “– +”). Group 1 (L228C–S232C) and group 3 (F241C–
I249C) residues displayed about 10–45% increase in disulfide formation upon incubation
with CuP in the absence of ligand compared to the untreated receptor. In contrast, upon
treatment with CuP in the absence of ligand group 2 (R233C–Q240C) mutants showed a
greater increase (54–96%) in percent of cross-linked receptor.
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Figure 3.4 Analyses of Ste2p dimerization in whole yeast cells. Cells expressing
various Ste2p IL3 cysteine mutants were permeabilized and exposed to CuP. (A) Images
of cells treated with various reagents used during the whole cell disulfide cross-linking
CuP treatment. (B) Blots of seven IL3 Cys mutants selected for whole cell cross-linking
evaluation. The samples were probed with anti-FLAG antibody to detect the presence of
Ste2p at either the monomer (M) or dimer (D) positions. Each preparation was untreated
(lanes −, −) or treated with β-ME (lanes −, +) or CuP (lanes +, −) or with CuP and β-ME
(lanes +, +). (C) A graph comparing the percentage of the Ste2p mutant receptors that
85

formed cross-linked dimers in membrane preparations and whole cells. (D) Whole cells
expressing receptors L228C and I249C were untreated or incubated with ligand prior to
Cu–P treatments. The blots were probed with anti-FLAG antibody to detect the presence
of Ste2p at either the monomer or dimer positions, respectively. Each preparation was
untreated (lanes −, −) or treated with Cu–P (lanes −, +) or with α-factor and Cu–P (lanes
α, +) or with α-factor antagonist and Cu–P (lanes a, +).

The high degree of disulfide cross-linking found in some of the IL3 Cys mutants
suggested that IL3 loops in two receptor subunits were within close proximity. However,
we were concerned that some of these protein–protein interactions may have been
artifacts related to the use of membranes. To determine whether disulfide formation was
the same or different in whole cells in comparison to membrane preparations, an in vivo
CuP treatment assay was performed. For this experiment we chose seven IL3 Cys
mutants representing each group in IL3 and treated these receptors with CuP in live
permeabilized cells (Figure 3.4). Microscopic observation (Figure 3.4A) showed that the
cells were not morphologically affected by CuP treatment, and these treated cells were
fully viable upon plating on growth media (data not shown). As was true with
membranes, the disulfide formation catalyzed by CuP was reversed to various extents in
the presence of β-ME (Figure 3.4B, +/+ lane). Comparison of the percent cross-linking in
membranes and whole cells (Figure 3.4B, immunoblots, and Figure 3.4C, bar graph
dimer/monomer ratio) showed that the trend for dimer formation in different IL3 mutants
was similar in both preparations. Dimerization of some mutants was reduced or
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disappeared upon α-factor addition; this together with the variations in the amount of
dimerization among the Ste2p-IL3 Cys mutants observed in at least three independent
experiments allows us to conclude that the dimer formation was reproducible and
specific.

Conformational Changes in TM5 and TM6 upon α-Factor Binding
In previous studies it has been shown that binding of α-factor affected Ste2p
dimer formation mediated through the TM regions, suggesting that these regions undergo
conformational changes(29, 34, 35). We investigated whether incubation with α-factor
would have any effect on CuP-mediated cross-linking of the IL3 mutants. While ligand
binding had only a minor effect on disulfide formation in receptors carrying mutations in
group 2 residues (Figure 3.3, R233C to Q240C, compare lanes “– +”and “+ +”), a
reduction in cross-linking was observed for mutation near TM5 (I230C and R231C) and
TM6 (F241C, S243C and H245C). Dimer formation was almost completely inhibited at
boundaries between IL3 and TM5 (L228C and A229C) and TM6 (L247C, L248C, and
I249C). The results suggest that α-factor binding induces conformational changes at the
TM5 and TM6 cytoplasmic ends of Ste2p that change the availability of the Cys residues
for chemical cross-linking, whereas in most of the IL3 loop the reactivity of these
residues is not affected by ligand binding. We observed similar inhibition of cross-linking
by α-factor in experiments using intact whole cells (Figure 3.4D).
A graphical representation showing the pattern of cross-link formation of IL3 Cys
mutants of Ste2p in the inactive (ligand unbound) and active (ligand bound) states is
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presented in Figure 3.5A. Analysis of the time course of disulfide (dimer) formation
(Figure 3.5B) showed that the TM5 (e.g., A228C) and TM6 (e.g., L248C) Ste2p mutants
formed dimers with a half-maximal time of about 3 min, whereas residues in the middle
of IL3 loop (e.g., F235C) exhibited half-maximal time of about 1.5 min. The slower
dimer formation at the TM5 and TM6 extracellular ends may suggest that these residues
are farther from each other compared to residues in the IL3 loop. It is clear from these
time course studies that formation of dimer is complete by 30 min under these
experimental conditions.

Figure 3.5 Dimer formation in Ste2p IL3. (A) Relative amount (%) of IL3-mediated
dimer formation in the presence and absence of pheromone. The graph was plotted from
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three independent experimental values. (*) The differences between the mean values
were statistically significant (P < 0.01). (B) Time course of dimer formation after CuP
treatment of Ste2p mutants L228C (TM5), F235C (IL3), and L248C (TM6). Preparations
were treated for the indicated time and then analyzed on Western blots for dimer
formation. Results represent the average of four to five independent experiments. Error
bars indicate the standard deviation.

α-Factor Antagonist Did Not Induce Conformational Changes in TM5 and TM6
Biochemical and cross-linking studies in our lab have shown that the N-terminus
of α-factor is necessary for activation but not binding to Ste2p (36-38). Recently, we
showed that Trp1 of α-factor interacts with Lys269 (TM6) of Ste2p (8). The question of
whether receptor activation involving the N-terminus of α-factor is important for the
changes in conformation at the cytoplasmic ends of TM5 and TM6 was investigated.
Membrane samples containing TM5 (L228C, A229C, I230C) and TM6 (I246C, L247C,
L248C, I249C) receptors were incubated with α-factor (WHWLQLKPGQPNle12Y) or an
α-factor antagonist (desW1,desH2-WLQLKPGQPNle12Y) prior to Cu–P treatment. The
results (Figure 3.6A, compare lanes label “α” and “a”) showed that, in contrast to the
native α-factor, treatment with antagonist did not significantly change the percent of
cross-linked product relative to that found in the unliganded receptor. Specifically for the
L228, A229, I230 L247, L248, and I249 Cys mutant receptors the cross-link percentages
for the unliganded and antagonist bound receptors were nearly identical, whereas
minimal cross-linking was found in the presence of α-factor. We also examined
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conformational changes in residues at positions 224–227 and 250–253 at the ends of the
TM5 and TM6 helices, respectively. Dimer (disulfide bond) formation was observed in
some residues (K225C, I227C, M250C, S251C, and Q253C) as shown in Figure 3.6B
that were also affected by the presence of α-factor, suggesting that the cytoplasmic ends
of the TM5/TM5 and TM6/TM6 helices in a dimeric receptor are indeed in very close
proximity and that they participate in the conformational change associated with ligand
binding.

Figure 3.6 Effects α-factor antagonist on dimerization of TM5 and TM6 Cys
mutants: (A) membranes from cells expressing Ste2p cysteine mutants at cytoplasmic
ends of the helices and (B) membranes from cells expressing Ste2p cysteine mutants in
helices that are suggested to be buried in the membrane were treated were incubated with
CuP in the presence or absence of α-factor or α-factor antagonist as described in the
Material and Methods. The membrane extracts were run on SDS-PAGE gels. The blots
were probed with anti-FLAG antibody to detect the presence of Ste2p at either the
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monomer (M, 53–55 kDa) or dimer (D, 106–110 kDa) positions. Each preparation was
untreated (lanes −, −) or treated with Cu–P (lanes −, +) or with α-factor and Cu–P (lanes
α, +) or with α-factor antagonist and Cu–P (lanes a, +).

GTP Did Not Affect Dimer Formation and Conformational Changes
The recent crystal structure of opsin with the 11 C-terminal residues of the Gα
protein led the authors to conclude that the active conformation of this GPCR was
stabilized by its interaction with Gα (10). Another study also reported GTP may affect the
interaction of receptor with Gα (39). We therefore determined whether the presence or
the absence of GTP would affect disulfide formation observed in this study. We
coexpressed the IL3 Cys mutants A228C and I249C with wild-type Gpa1p under the
control of the same promoter in order to maintain equal level of the receptor and its Gα
protein and repeated the Cu–P treatment in the presence of GTP-γ-S. The results (Figure
3.7A) suggest that GTP-γ-S addition had no effect on the level of disulfide formation,
indicating that Gα protein activation is not required for the observed conformational
changes. In contrast, when cross-linking was carried out in a Gpa1p deleted strain (Figure
3.7B), the level of disulfide formation in the presence of ligand was not significantly
reduced at the TM5 and TM6 ends in comparison to that observed in the Gpa1p
background (Figures 3.7A, 3.3, and 3.6A).
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Figure 3.7 Effects of G protein expression and activation on TM5 and TM6 ligand
induced conformational changes. (A) Whole cell membranes containing receptors
A228C and I249C were treated with or without ligand in the presence or absence of 0.1
mM GTP-γ-S prior to Cu–P treatments. The blots were probed with anti-FLAG antibody
to detect the presence of Ste2p at either the monomer (M, 53–55 kDa) or dimer (D, 106–
110 kDa) positions. Each preparation was untreated (lanes −, −) or treated with Cu–P
(lanes −, +) or with α-factor and Cu–P (lanes α, +) or with α-factor antagonist and Cu–P
(lanes a, +). (B) Analyses of Ste2p dimerization in yeast cells (TM5117) devoid of Gα
protein. Whole cell membranes containing Cysless, A228C, L236C, and I249C Ste2p,
from cells lacking Gα were treated with or without ligand prior to Cu–P treatments. The
blots were probed with anti-FLAG antibody to detect the presence of Ste2p at either the
monomer or dimer positions.

92

Chapter 4
Discussion
We have used disulfide cross-linking analysis to probe conformational changes
of residues in the third intracellular loop (IL3) and the ends of the contiguous fifth (TM5)
and sixth (TM6) transmembrane domains of Ste2p during ligand-induced activation. An
assumption of this approach is that the cysteine mutations may act as surrogates of the
native residues in Ste2p. Therefore, it is critical that the mutations not affect the activity
of the receptor, its conformation, or its spatial relationships to other receptor molecules or
interacting proteins. Several studies have reported that individual residue mutations in
Ste2p IL3 did not significantly affect receptor activity (15-17). Consistent with previous
studies (31), Ste2p with mutations in IL3 was observed to tolerate Cys substitutions in
our experiments except for the K225C receptor. The tolerance for substitutions in IL3
suggests that the contact points revealed in the cross-linking analysis likely exist in the
native receptor and that activation of G protein by Ste2p involves multiple intermolecular
interactions as observed for mammalian GPCRs (40, 41).
Given that IL3 has been suggested to be involved in receptor-Gα protein (Ste2p–
Gpa1p) interactions (15-17), it is interesting that strong dimer formation occurred in the
IL3 Cys mutants. This is consistent with the conclusion that IL3 in rhodopsin has been
identified to play a role in receptor oligomerization (42-44). In addition, molecular
dynamics simulations, correlated-mutation analysis, and evolutionary-trace analysis all
predict the involvement of IL3 in GPCR dimerization (32). The dimer formations
observed in our study were also detected in intact cells, indicating that the disulfide bond
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formation between the two monomers of Ste2p occurs in the native environment of the
receptor. Substitution cysteine accessibility studies on Ste2p-IL3 residues suggested all
the residues, L228–I249, were accessible, and even though residues I246C and L247C
were about 2-fold more accessible than most IL3 (R233–Q240) residues (31), in our
study when treated with CuP these residues (I246C, L247C) exhibited only 22–30%
dimer formation compared to the 54–96% dimer formation found for residues R233C–
Q240C. In addition, though K225C, I227C, M250C, S251C, and Q253C at the
cytoplasmic ends of the TM5 and TM6 helices have been shown to be buried in the
membrane and not solvent accessible (31), we observed disulfide formation involving
these residues that was reduced by the presence of α-factor, suggesting that the
cytoplasmic ends of the TM5/TM5 and TM6/TM6 helices in the inactive state of Ste2p
are in closer proximity than when activated by ligand. The differences in the results of the
cysteine accessibility and disulfide cross-linking studies of Ste2p IL3 cysteine mutants
suggest that the cross-linking (dimer formation) that we observed is not due to the fact
that these residues are accessible and randomly cross-linking. Rather, we suggest that
these results indicate that specific residues in the IL3 region are in positions and
orientations that permit disulfide bond formation while others are not, irrespective of
their accessibility.
The IL3 of Ste2p has been suggested to have the potential to form an α-helix with
a distinct amphipathic character (45). The pattern of disulfide formation in our study,
with R233C, L236C, and K239C mutant receptors having the highest percent of disulfide
formation (Figures 3.3 and 3.5), suggests that the group 2 residues in IL3 (R233–Q240)
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may form a 310 helix as shown in Figure 3.8A. The Phyre structural bioinformatics group
tools (30) also predicted a 310 helix in the 3-D structure of IL3 (Figure 3.8B) consistent
with our cross-linking studies. The IL3 310 helix (RRFLGLKQ) is highly positively
charged. It might be expected that in the wild-type Ste2p dimer there should be charge
repulsion between IL3 loop residues in the two Ste2p monomers. However, in the
mutants studied herein the data strongly suggest that the substituted Cys residues are
close enough to effectively form disulfide bonds. One might suggest that the Cys
substitution alone changes the physical chemical characteristics of the loop leading to
non-native interactions. However, the L236C mutant still contains all three positive
residues (R233, R234, and K239) yet is capable of forming about 95% dimer, indicating
that the IL3 residues in the dimeric receptor are indeed in very close proximity. We
conclude that in native dimers of Ste2p the IL3 residues are close enough to make
contacts that can be captured in disulfide cross-linking experiments. As pointed out by
others, the interpretation of such dimers in terms of receptor function must be tempered
by the possible changes in the monomer–dimer equilibrium that are effected by chemical
cross-linking (29, 35).
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Figure 3.8 Helical wheel projections and 3D model of IL3 residues involved in
Ste2p–Ste2p interactions. (A) The IL3 residues R233 to Q240 are suggested to form a
310 helix structure with a periodicity of 3.2 residues per turn in the helical wheel (46). (B)
The 3D structure of two Ste2p molecules showing regions TM5, TM6, and IL3 with a
310 helix in IL3 as predicted by the Phyre Structural Bioinformatics Group prediction
tools (30). The IL3 310 helixes of two Ste2p subunits are suggested to be in close
proximity that permit disulfide cross-linking. (C) A schematic diagram showing possible
shifts at the cytoplasmic ends of TM5 and TM6 upon ligand binding. The vertical arrows
indicate a shift of the TMs away from each other.
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A previous study used limited trypsin digestion of Ste2p to identify
conformational changes induced by the binding of α-factor. The presence of α-factor
caused the third intracellular loop of the receptor to become more accessible to trypsin,
suggesting that α-factor binding to Ste2p-induced conformational changes of IL3 (19).
However, specific residues or regions of the IL3 involved in such changes were not
identified. As judged by their availability to form disulfide cross-links, our data suggest
that the residues in the middle of IL3 do not undergo conformational change, whereas the
residues at the TM5–IL3 and IL3–TM6 boundaries do, leading to a change in their
availability for disulfide formation.
The recent crystal structure of chemokine receptor, CXCR4, in the dimer form
suggests that the monomers interact only at the extracellular side of helices TM5 and
TM6 to play an important role in stabilizing the dimeric receptor (7). Our results suggest
that Ste2p TM5/TM5 and TM6/TM6 interact at the cytoplasmic ends. We propose that
the Ste2p residues in TM5 (K225, I227, L228, A229, I230) and in TM6 (L247, L248,
I249, S251, and Q253) at the cytoplasmic ends may be involved in Ste2p–Ste2p
interactions. Such interactions are disrupted upon ligand binding as shown by the
disappearance or reduction of disulfide-mediated dimerization of the various Cys mutants
in the presence of α-factor. The α-factor induced similar changes in the cross-linking of
the various receptors in intact whole cells (Figure 3.4D). Since in this latter experiment αfactor should only bind to the receptors at the cell surface (at the plasma membrane), the
results suggest that the changes at the TM5 and TM6 cytoplasmic ends found in disulfide
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cross-linking experiments reflect the native state of these receptors. Disulfide crosslinking efficiencies reflect both the spatial proximity of the sulfhydryl groups and their
mobility. Thus, changes in conformation at the ends of TM5 and TM6 upon α-factor
induced Ste2p activation can be inferred from the data. Another possibility is that αfactor activation changes the flexibility of these regions of Ste2p. A model consistent
with our experimental data would have the TM5 and TM6 ends of a Ste2p dimer shift
away from each other so that it is not possible to form a disulfide bond as shown in
Figure 3.8C. A similar reorientation of TM5 and TM6 has been proposed for activated
forms of mammalian GPCRs (11, 47-49) and shown recently in a series of X-ray
crystallographic studies (12-14, 50). Antagonist-bond dopamine receptor also showed
reorientation of TM regions (50).
It is possible that the 100 kDa band observed in the gels represents interaction of
Ste2p with some protein other than itself. The fact that all Ste2p Cys mutants we
examined form this band makes this possibility highly unlikely. In addition, a number of
papers (8, 22, 23, 29, 35, 51-54) showed that Ste2p labeled by a variety of epitopes
(FLAG, MYC, RHO) react with antibodies to these epitopes at positions in the gels that
correspond to the molecular weight of a dimer of Ste2p. The antibodies react with no
other bands except proteins at the Ste2p dimer or monomer position in these SDS-PAGE
immunoblots. Similar results are obtained with an antibody generated against the Nterminus of Ste2p. Furthermore, purified Ste2p confirmed by MALDI-TOF and
nanospray MS exhibits a 100 kDa at the same position we have attributed to the Ste2p
dimer (55). Most importantly, the major conclusion of this paper is that the results
98

indicate that the cytoplasmic ends of TM5 and TM6 undergo conformational change
upon ligand binding. This conclusion would remain even if there were a second partner.
At the TM6 cytoplasmic end, residues L247, L248 I249, M250, S251, and Q253 all
formed about 10–20% Ste2p-Ste2p dimers; however, in the presence of ligand the
percent of Ste2p–Ste2p dimer is greatly reduced, and residues L247C and I249C interact
with Gpa1p (Umanah, unpublished). The switch of L247C and I249C from involvement
in Ste2p–Ste2p interaction in the inactive state to Ste2p–Gpa1p heterodimer interactions
in the active state would be consistent with a clockwise rotation of this region of the
receptor as observed in other mammalian GPCRs (11, 47-49). In the inactive state the
TM5 cytoplasmic ends residues K225, I227, L228, A229, and I230 also formed about
10–15% Ste2p–Ste2p homodimers, and in the presence of ligand, these residues
displayed reduced Ste2p–Ste2p homodimer formation and L228C formed a Ste2p–Gpa1p
heterodimer (Umanah, unpublished). We therefore propose that the TM5 cytoplasmic end
undergoes a counterclockwise rotation as observed in other GPCRs (56).
Previously, we showed that Ste2p Tyr266 (on the extracellular end of TM6)
interacted with Asn205 (on the extracellular end of TM5) only in the active conformation
of the receptor (57), suggesting that these extracellular regions of the Ste2p TM5 and
TM6 undergo conformational changes upon α-factor binding. Thus, our cross-linking
results would support a model where binding of α-factor to Ste2p leads to conformational
changes at the extracellular regions of TM5 and TM6 which are propagated to the
cytoplasmic ends of these helices and result in exposure of L247C, L248, and I249C for
activation of Gα.
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The N-terminus of α-factor pheromone has been suggested to interact with Ste2p
residues, S251–M294 which comprises part of TM6, the third extracellular loop, and part
of TM7 (36-38). Recently, we show that Trp1 of α-factor interacts with K269 located at
the extracellular boundary of TM6 (8). Previous studies showed that the α-factor
antagonist was capable of competing out α-factor binding to Ste2p but did not exhibit
measurable biological activities, suggesting that the interactions of the first two amino
acids of α-factor with residues at extracellular regions of Ste2p TM5/TM6 are critical for
receptor activation. The experiments presented in this study suggest that the antagonist
was not able to block or reduce disulfide formation compared to the native α-factor,
implying that antagonist binding to Ste2p does not induce the conformational changes or
changes in flexibility at the TM5 and TM6 cytoplasmic ends.
It has been shown that the exchange of GDP for GTP in Gα proteins during receptor
activation is induced by interactions of Gα with the receptor during activation and also
that GTP binding to Gα may affect ligand affinity for its GPCR (1). The addition of GTPγ-S to membrane fractions prior to CuP treatment to induce disulfide cross-linking did
not have any observable effects on dimer formation though Ste2p and Gpa1p were
expressed under the same promoter. Cross-linking carried out in a Gpa1p deleted strain
was not affected by a large excess of agonist, suggesting that Gpa1p–Ste2p interactions
may influence conformational changes or changes in side chain flexibility at the
cytoplasmic ends of TM5 and TM6. We conclude that the putative conformational
changes at the cytoplasmic ends of TM5 and TM6 in Ste2p require interactions of the N-
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terminal amino residues of α-factor and are affected by the interactions with Gα, but not
by Gα activation.
In conclusion, we show for the first time changes in receptor conformation or
flexibility that influence the availability for disulfide formation of residues in the region
of IL3 of Ste2p close to the contiguous TM5 and TM6 helices. The hydrophilic residues
located

in

the

middle

of

the

IL3

loop

(R231–Q240)

do

not

change

conformation/availability during receptor activation, whereas many hydrophobic residues
at the TM5 and TM6 cytoplasmic junctions do. These conformational changes require
ligand-induced activation of Ste2p and appear to depend on Ste2p–Gα protein
interactions. The pattern of disulfide formation observed is consistent with a 310 helical
structure in the center of IL3 and suggests that the IL3 loop of two Ste2p subunits remain
in close proximity both in the active and inactive states of the receptors. Since Ste2p has
been shown to have structure–function relationships similar to the physiologically and
pharmacologically important rhodopsin-like GPCR family (58), the role of IL3 observed
in this study has implications not only for Ste2p but also other GPCR systems.
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PART IV
Residue-to-Residue Interactions Between a G Protein-Coupled Receptor
(GPCR) and its Gα Protein in the Saccharomyces cerevisiae Model
System

111

Part IV presents collaborative work with Dr. Fred Naider’s laboratory at the City
University of New York, Staten Island. Li-Yin Huang and George K. E. Umanah
performed most the work, Julie Maccarone assisted with the phenotypes of the Gpa1p
mutants and the peptides used were obtained from Dr. Naider’s laboratory.
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Abstract for Part IV
Understanding the interactions between G protein-coupled receptors (GPCRs) and
their cognate Gα proteins is an important goal for drug discovery as interference or
enhancement of this interaction will directly modify signal transduction. Ste2p, the
GPCR for the tridecapeptide pheromone α-factor of Saccharomyces cerevisiae, has been
used extensively as a model for investigating GPCR structure and function as Ste2p has
structure-function relationships similar to mammalian GPCRs. Using cysteine disulfide
cross-linking we have identified specific residue-to-residue interactions between Ste2p
and Gpa1p, its Gα protein. Using combinatorial expression and assay of 242 Ste2p and
Gpa1p cysteine mutants, five Ste2p residues located at the cytoplasmic ends of the fifth
and sixth transmembrane domains were identified to interact with five residues of the Cterminus of Gpa1p. Different cross-linking reactions of the Ste2p residues with Gpa1p
residues in the absence and presence of the α-factor pheromone suggested that during
activation both transmembrane 5 and 6 of Ste2p and the α5-helix (C-terminus) of Gpa1p
undergo conformational changes that results in withdrawal of the α5-helix from the
receptor. This study is the first to identify specific residue-to-residue interactions between
a GPCR and its cognate Gα protein in its active and inactive states.
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Chapter 1
Introduction
G protein-coupled receptors (GPCRs) are medically important receptors that are
comprised of seven transmembrane domains (TMs) and function by activating
heterotrimeric G proteins. These receptors are the most diverse group of membranebound receptors and are the targets of a multitude of current prescription drugs (1-3).
Despite the availability of crystal structures for GPCRs (4) and G proteins (5, 6), the
molecular mechanisms leading to activation of G proteins upon ligand binding to GPCRs
remain unclear. GPCR–G protein interactions have implications with regards to drug
discovery:

If drugs can be identified that interfere or promote GPCR-G protein

interaction, change the pattern of GPCR–G protein associations, or cause a GPCR to
preferentially associate with one G protein and not others, then it would be possible to
regulate the activities and functions of a specific receptor (1, 7-9).
The mating pathway of Saccharomyces cerevisiae has been a valuable tool for
studying GPCR signal transduction mechanisms for many reasons including the fact that
the yeast mating pheromone receptors activate only one Gα (Gpa1p) making the yeast
system highly amenable to identification of specific interactions between the receptor and
a Gα (10-12). Ste2p, the α-factor pheromone receptor of S. cerevisiae, shows an overall
similar structural architecture to mammalian GPCRs and Gpa1p shows about 45%
sequence similarity with various mammalian Gα proteins (13). Comparison of Ste2p with
the rhodopsin (class A) subfamily of GPCRs suggests that there are underlying
similarities in the mechanism of signal transduction between Ste2p and the Class A
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GPCRs (11). These characteristics of Ste2p make it a good model for peptide-responsive
GPCRs.
Studies on the interactions between Ste2p and Gpa1p indicate that the Ste2p third
intracellular loop (IL3) is involved in Gpa1p activation (14-17). Like the mammalian Gα
proteins, the region of Gpa1p that has been most commonly predicted to interact with
Ste2p is the C-terminus (18, 19). Despite the intense studies carried out on the
interactions of Ste2p with Gpa1p, the specific residue-to-residue interactions between
Ste2p and Gpa1p have not been determined.
Several models have been proposed for signal transfer from the activated receptor
to the Gα protein. The “gear shift”, “lever arm” and “sequential fit” models have in
common that the α5 helix (C-terminus) of Gα is the key transmission domain for the
receptor-G protein signal transfer (20). The binding of Gα to the activated receptor is
suggested to cause movement of the α5 helix that affects GDP binding at the β6-α5 loop
(21). Recently, using structural and kinetic modeling of the C-terminus of transducin, Gα
was proposed to undergo rotational and translational movements during activation (20). It
has also been suggested that the receptor must induce conformational changes in the G
protein that result in the exchange of GDP for GTP (22). Evidence for this complex series
of interactions and for structural transitions in the G protein have also been
experimentally determined using spin-labeled, reconstituted Gαi and rhodopsin (21).
This study identifies specific residue-to-residue interactions between Ste2p and
Gpa1p in both the activated and inactive state using biochemical analysis by disulfide
cross-linking. The patterns of Gpa1p interaction with the inactive and active forms of
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Ste2p suggest possible rotational and “withdrawal” movements at the C-terminus of
Gpa1p that are required for proper Ste2p coupling and Gpa1p activation.

These

experimental conclusions are used to develop a proposed mechanism for Ste2p-Gpa1p
signal transfer. The approaches and information from this study will be valuable for
future studies on mammalian GPCRs signaling pathways.
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Chapter 2
Material and Methods
Media, Reagents, and Strains and Transformation
Saccharomyces cerevisiae strains LM102 [MATa, bar1, leu2, trp1, ura3, FUS1lacZ::URA3, ste2∆ (23)] and TM5117 [MATa, bar1, leu2, his3, ura3, FUS1-lacZ::URA3,
ste2∆, gpa1∆ (23)] were used for biological activity assays and the protease-deficient
strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (24)] was
used for protein isolation and immunoblot analysis. The STE2 and GPA1 mutant
plasmids were transformed by the method of Geitz (25) into the S. cerevisiae strains.

Cysteine Scanning Mutagenesis
C-terminal FLAG™ and His tagged STE2 with the two cysteine residues (Cys59
and Cys252) substituted with serine and cloned into the plasmid p424-GPD to yield
plasmid pBEC2 (23, 26) was used for expressing Ste2p. The plasmid pBEC2 was
engineered by site-directed PCR mutagenesis to replace 22 residues, one at a time, in
Ste2p (Ala228-Ile249) with cysteine. The open reading frame of GPA1 was PCR amplified
from the plasmid YepGαβγ (27) and cloned into the plasmids p426 and p423-GPD (28)
to yield plasmids pBUG6 and pBUG3 for expression in the BJS21 and TM5117 strains,
respectively. The pBUG6 and pBUG3 were engineered by site-directed mutagenesis to
replace 11 residues in Gpa1p (Ile461-Ile471) with cysteine. The sequence of all cysteine
mutants was verified by DNA sequence analysis completed by the molecular biology
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resource facility located on the campus of the University of Tennessee. Mutagenic and
sequencing primers were purchased from Invitrogen (Carlsbad, CA).

Membrane Extraction and Immunoblots
BJS21 cells expressing STE2 and GPA1 mutant constructs grown in selective
media were used to prepare total cell membranes isolated as previously described (29).
Membrane extracts were resuspended in HEPES buffer (50 mM HEPES, 150 mM NaCl,
pH 7.5, 20% glycerol). For immunoblotting blots were probed with FLAG™ antibody
(Sigma/Aldrich Chemical, St. Louis, MO) to detect Ste2p or an antibody directed against
Gpa1p (Santa Cruz Biotechnology, Inc., CA). The signals generated were quantitated
using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation
system (BioRad, Hercules, CA) to determine expression levels.

Growth Arrest Assays
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at
30 ºC in MLT (minimal medium (30) lacking tryptophan), harvested, washed three times
with water and resuspended at a final concentration of 5 x 106 cells/ml (24). Cells (1 ml)
were combined with 3.5 ml agar noble (1.1 %) and poured as a top agar lawn onto MLT
medium agar plates. Filter disks (BD, Franklin Lakes, NJ) impregnated with α-factor
pheromone (0.125 – 2.0 μg) were placed on the top agar. The plates were incubated at
30ºC for 18 hours and then observed for clear halos around the discs. The diameter of
halos around the discs were measured and analyzed by linear regression analysis using
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Prism software (GraphPad Software, San Diego, CA). The experiment was repeated at
least three times and reported values represent the mean of these tests.

Fus1-lacZ Assays
LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants
were grown at 30ºC in selective media, harvested, washed three times with fresh media
and resuspended at a final concentration of 5 x 107 cells/ml.

Cells (0.5 ml) were

combined with α-factor pheromone (final concentration of 1 μM) and incubated at 30ºC
for 90 minutes. The cells were transferred to a 96-well flatbottom plate in triplicates,
permeabilized with 0.5% Triton X-100 in 25 mM PIPE buffer and then β-galactosidase
assays were carried out using fluorescein di-β-galactopyranoside (Molecular Probes, OR)
as a substrate (31). The reaction mixtures were incubated at 37ºC for 60 minutes and 1.0
M Na2CO3 was added to stop the reaction. The fluorescence of the samples (excitation of
485 nm and emission of 530 nM) was determined using a 96-well plate reader Synergy2
(BioTek Instruments, Inc., Winooski, VT). The data were analyzed using Prism software
(GraphPad Software, San Diego, CA). The experiments were repeated at least three
times and reported values represent the mean of these tests.

Saturation Binding Assay
Tritiated α-factor (9.3 Ci/mmol) was used in saturation binding assays on whole
cells. LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants were
harvested, washed three times with YM1 [yeast minimum medium with 0.5 M potassium
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phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium
fluoride, and 1% BSA], and adjusted to a final concentration of 4 × 107 cells/ml in
binding medium YM1i (YM1 plus protease inhibitors). Cells (630 μl) were combined
with 70 μl of 10X YM1i supplemented with [3H]α-factor and incubated at room
temperature for 30 min. The final concentration of [3H]α-factor ranged from 0.4× 10–9 to
50 × 10–9 M. Upon completion of the incubation interval, 200 μl aliquots of the cell–
pheromone mixture were collected in triplicate and washed over glass fiber filter mats
using the Standard Cell Harvester (Skatron Instruments, Sterling, VA). Retained
radioactivity on the filter was counted by liquid scintillation spectroscopy. LM102 cells
lacking Ste2p were used as a nonspecific binding control for the assays. Specific binding
for each mutant receptor was calculated by subtracting the nonspecific values from those
obtained for total binding. Specific binding data were analyzed by nonlinear regression
analysis for single-site binding using Prism software (GraphPad Software, San Diego,
CA) to determine the Kd (nM), and Bmax values (receptors/cell) for each mutant receptor
were calculated. The final values represent the binding constants from at least three
independent experiments.

Disulfide Crosslinking
Membrane samples were incubated with or without Cu-P (1.0 μM Cu and 3.0 μM
1,10-phenanthroline) in the absence or presence of a saturating amount of α-factor (5 μM)
at room temperature for 30 min and then quenched by addition of EDTA (10 mM). The
membrane samples were resuspended in non-reducing SDS sample buffer (BioRad,
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Hercules, CA), separated by 10% SDS-PAGE, and then analyzed by immunoblotting as
previously described (29). The disulfide reaction was reversed by reducing with 4% 2mercaptoethanol (β-ME) in the SDS sample buffer. For in vivo cross-linking, cells were
grown to mid-log phase, harvested, and washed with water by centrifugation (4000g for 5
min). The cells were resuspended in 100 mM LiAc and incubated at 30ºC for 30 min with
mixing. After centrifugation, the cells were resuspended in 25% PEG with 250 mM LiAc
for another 60 min incubation. Cells were washed with HEPES buffer three times after
LiAc treatment. To evaluate the effect of receptor activation on in vivo crosslinking,
whole cells were first incubated with KF (10 mM) and NaN3 (10mM) in HEPES buffer at
room temperature for 15 min to inhibit receptor endocytosis (32) and then α-factor was
added to a final concentration of 5 μM. Disulfide cross-linking was induced by adding
Cu-P to final concentrations of 0.5 mM Cu and 1.5 mM 1,10-phenanthroline as
previously described for whole cell experiments in yeast (33). Membrane extraction was
carried as described above with HEPES buffer containing 10 mM EDTA/NEM.

Prediction and Modeling
All models of 3-D structures were generated by the Phyre Structural
Bioinformatics Group prediction tools (34). The structures were viewed and labeled with
the PyMOL pdb viewer software (DeLano Scientific LLC, Palo Alto, CA). Aligment of
the last 11 amino acids of transducin (Gα of rhodopsin) with Gpa1p was carried out using
European

Bioinformatics

Institute

online

sequence

alignment

tools

(http://www.ebi.ac.uk/).
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Chapter 3
Results
Phenotypes of Ste2p IL3 Cys Mutants
The Cys-less Ste2p (C59S and C252S), with FLAG™ and HIS-epitope tags in the
C-terminus, engineered as the background for the specific cysteine mutations has been
previously shown to have expression levels and biological activities identical to those of
the wild type receptor as determined by several assays (23, 26). Substitution of single
cysteine residues from L228C through I249C in intracellular loop 3 (IL3) of Cys-less
Ste2p resulted in constructs that were expressed and had biological activities identical or
similar to (within 25% of Cys-less, except for R233C, L236C, and K239C) that of the
Cys-less receptor (see Table 4.1). In addition to quantitation of the Western blot signals,
saturation binding assays were carried out on selected mutants (L228C and A229C from
the TM5-IL3 boundary, R233C and R234C from the middle of IL3, and L248C and
I249C from the IL3-TM6 boundary). The receptors showed almost equal Kd values for
ligand binding and were expressed at levels within 12% difference (L228C, A229C,
L248C, and I249C) to about 55-63% (R233C and R234C) of the Cys-less control
respectively (Figure 4.1). Since the A229C mutant does not crosslink whereas the L228C,
L248C and I249C do, we conclude that the expression levels are not the reason for the
differences in crosslinking we noted.
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Table 4.1 Summary of phenotypes of Ste2p IL3 Cys substitution mutants. The
expression levels as measured by western blots and biological activities all had standard
deviations between ±4 and ±7 percent. All assays were done three times independently.
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Figure 4.1 Whole cell saturation binding assay of [3H]α-factor to Cysless and IL3
Cys mutant receptors. A graph of CPM (count per minute of radioactivity of cells)
versus the concentration of the [3H]α-factor is shown. The data represents specific
binding to cells as determined by subtracting the binding to cells lacking the receptor
from binding to cells containing the containing Ste2p Cys mutant receptors. Below the
graph is a table containing a summary of the binding affinities (Kd) and surface
expression of the receptors.
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Expression and Activities of Gpa1p Cys-Mutants
Most of the cysteine residues in Gpa1p are localized within highly conserved
stretches of Gpa1p that share about 45% amino acid identity to transducin (17). In
addition some of these cysteine residues, especially C3, are very important for biological
activities such as thioacetylation, palmitoylation, signaling, and membrane localization
(35). Thus, we did not mutate the endogenous Cys residues, because we were concerned
that removing these cysteine residues would affect the localization and signaling of the
Gpa1p. The Gpa1p Cys mutants generated in this study have expression levels similar to
wild type Gpa1p (Figure 4.2A). A high molecular weight protein [denoted as a nonspecific (NS) signal] that reacted with anti-Gpa1p was seen in all samples and also in
extracts from TM5117 cells that were deleted for Gpa1p. The yeast strain TM5117 used
to express the Gpa1p mutants has the endogenous GPA1 deleted resulting in high FUS1lacZ activities in the absence of pheromone because the Gβγ subunits constitutively
activate the signal transduction pathway (Figure 4.2B). Expression of the mutant Gα
subunits with the various Cys-substituted mutations showed that all could interact with
the endogenous Gβγ subunits leading to reduced FUS1-lacZ activities in the TM5117
yeast strain in the absence of pheromone (Figure 4.2B). In the presence of α-factor, the
FUS1-lacZ activities increased, implying that all of the Gα mutants can couple
productively with both the Ste2p receptor and the G protein βγ subunits. However, the
mutants K468C, I469C and I471C exhibited about 60-70% capacity to activate signal
transduction as measured by FUS1-lacZ activity in comparison to the other Cys-mutants.
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Figure 4.2 Expression and signaling activity of Gpa1p Cys-mutants. A: Immunoblot
of Gpa1p Cys mutants probed with anti-Gpa1p. NS represents a non-specific reactive
band. B: β-galactosidase activity from the induction of the reporter gene Fus1-LacZ by
activation of Ste2p mediated signaling in strains containing Gpa1p Cys mutants with
(gray bars) and without (black bars) added pheromone. The data is normalized to activity
in the Gpa1p-deleted mutant. C: Sequence alignment of eleven amino acids of Gpa1p and
transducin at C-terminal end.
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Disulfide Crosslinking of Ste2p and Gpa1p
The molecular weight of the epitope tagged Cys-less Ste2p used to generate the
IL3 Cys mutants is about 51 kDa. This receptor is normally observed as a monomer (5155 kDa, appearing with three bands due to N-glycosylation at two sites on the Nterminus) and a dimer (106-110 kDa) on blots (23). The wild type Gpa1p used in this
study is observed at 52-54 kDa (Figure 4.2A). The Ste2p-Gpa1p disulfide crosslinked
product (~103-108 kDa) is therefore expected to be at a position similar to that of the
Ste2p dimer (~102-110 kDa) on immunoblots. Since the IL3 Cys mutants have been
shown to form homo-dimers we needed to differentiate a 103-108 kDa Ste2p homodimer
band from a Ste2p-Gpa1p heterodimeric cross-linked product at a similar position on
immunoblots. To detect the Ste2p-Gpa1p cross-linked product we used an antibody
directed against Gpa1p. This antibody reacted with the 52-54 kDa (Gpa1p) band and
detected a 103-108 kDa Ste2p-Gpa1p heterodimer since Gpa1p does not form a
homodimer. As seen in Figure 4.2A the wildtype Gpa1p and its Cys analogs exhibit only
one strong band at the molecular weight expected for the monomer (~52 kDa). All of the
Gpa1p constructs and the Gpa1p deletion strain exhibit a very weak band at a high
molecular weight (~130 kDa). These results clearly show that Gpa1p and the Cys analogs
examined herein do not form homodimers.
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To determine whether IL3 residues (L228-I249) in Ste2p interacted with the Cterminal (I461-I471) residues in Gpa1p as measured by disulfide crosslinking, the IL3
Cys-mutants were each co-expressed with all the Gpa1p Cys-mutants including wild type
Gpa1p. Thus 23 different IL3 receptors (22 with one Cys residue in IL3 and the control
Cys-less Ste2p) were co-expressed with 12 different Gpa1p proteins (11 with one Cys
residue in the C-terminus and the control Gpa1p without Cys) to give 276 different
combinations of Ste2p/Gpa1p. Membranes extracted from all of the different
combinations were incubated with or without 5 μM α-factor to activate Ste2p and then
treated with Cu-P to facilitate Cys-Cys disulfide formation (36). To illustrate the Ste2pGpa1p cross-linking results we compare Ste2p-I246C, Ste2p-L247C and a Cys-less Ste2p
control interacting with various Gpa1p Cys mutants (Figure 4.3). Of the 36 expression
combinations shown in Figure 4.3, only 2 (Ste2p-L247 C with either Gpa1pN465C or
Gpa1pK467C) showed bands at the position expected for a Ste2p-Gpa1p crosslinked
product. These are indicated by asterisks in the Figure. Interestingly, the L247C-N465C
crosslink is formed only in the absence of α-factor whereas the L247C-K467C crosslink
is formed only in the presence of the pheromone. To determine whether the endogenous
cysteine residues in Gpa1p could cross-link to Ste2p, all the Ste2p Cys mutants that we
generated were co-expressed with the wildtype Gpa1p (containing all endogenous
cysteine residues) for cross-linking as shown in blots in Figure 4.3. We did not observe
any cross-linking between the wildtype Gpa1p and any of the Ste2p Cys mutants. Thus
the endogenous cysteine residues were not involved in Ste2p-Gpa1p crosslinking.
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Figure 4.3 Immunoblots of two cysteine mutants of the IL3 region of Ste2p
co-expressed with eleven Gpa1p Cys-mutants probed with anti-Gpa1p. Membrane
preparations from transformants that were untreated (lanes -, -), treated with Cu-P in the
absence of α-factor (lanes -, +) or treated with Cu-P in the presence of α-factor (lanes +,
+) were probed with anti-Gpa1p antibody to detect the presence of Gpa1p (Gα) at either
the 52-54 kDa or 103-108 kDa (Ste2p-Gα cross-linked) position. The samples were
resolved on 10% SDS-PAGE. The blot images were spliced together from different gels
to place the mutants in order according to the residue number of the Gpa1p cysteine
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replacement. The top panel is data from a Ste2p Cys-less strain co-transformed with
various Gpa1p Cys mutants. The middle and bottom panels present similar experiments
from Ste2p-I246C and Ste2p-L247C, respectively. The combinations that showed
crosslinks are designated with asterisks.

Ste2p: TM5 C228 A I R S R R F L G L K Q F D C243 F H C247 C248 C249 TM6

Gpa1p:

I461 I C463 Q C465 L C467 K C469 C470 I471

Ste2p-Gpa1p cross-linking in ground state
Ste2p-Gpa1p cross-linking in ligand bound state
Figure 4.4 Diagrammatic representation of cross-links formed between Ste2p and
Gpa1p Cys-substituted mutants in the active and inactive state. The cysteine residue
is that which would be present in the individual mutated Ste2p or Gpa1p proteins.

Out of the 22 Ste2p Cys-mutants tested, 5 mutants (L228C, S243C, L247C,
L248C and I249C) showed a cross-linked band with 5 out of the 11 Gpa1p Cys-mutants
(Q463C, N465C, K467C, I469C and G470C) in either the ligand-unbound or ligandbound state of Ste2p (schematically indicated in Figure 4.4). Examination of all the antiGpa1p blots quantitatively showed that the NS signal intensity varied and was
independent of the Ste2p-Gpa1p signal. Furthermore, CuP catalyzed oxidation in the
absence of alpha-factor or in the presence of alpha-factor resulted in a quantifiable
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reduction in Gpa1p when the crosslinked heterodimer Ste2p-Gpa1p was formed, and the
sum of the band intensities of Ste2p-Gpa1p and Gpa1p are in reasonable agreement with
the intensity of Gpa1p in the untreated control. We conclude that the weak NS signal can
not be related to the amount of Gpa1p or Ste2p-Gpa1p in the sample.

Figure 4.5 Immunoblots of various combinations of Ste2p and Gpa1p Cys mutants
probed with anti-FLAG™ antibody (anti-Ste2p) and anti-Gpa1p. The samples were
resolved on a 4-12 % gradient SDS-PAGE. A: The blots were probed with anti-FLAG to
detect the presence of Ste2p at either ~51-55 kDa (Ste2p monomer) or ~108-110 kDa
(Ste2p-dimer) or ~103-108 kDa (Ste2p-Gα cross-linked) position. B: The blots were also
probed with anti-Gpa1p antibody to detect the presence of Gpa1p (Gα) at either the ~53131

54 kDa (monomer) or ~103-108 kDa (Ste2p-Gα cross-linked) position. The blot images
were

spliced

together

from

different

gels.

The

last

two

combinations

Ste2p(I249C)/Gpa1p(470C) were run in the presence and absence of 4% βmercaptoethanol.

The Gpa1 polyclonal antibody (Santa Cruz) was generated to a peptide
comprising residues 183-472 (290 residues) of Gpa1p, so that this polyclonal antibody
was expected to react with Gpa1p with single cysteine mutations within the small region
(461-471) tested in our studies and also detect Gpa1p crosslinked through its extreme Cterminus to Ste2p. To confirm that the signal on the anti-Gpa1p blots are indeed Ste2pGpa1p cross-linked all the Cu-P treatments of mutants with detectable cross-linked
products were probed using both anti-Gpa1p (Figure 4.5B) and anti-FLAG (Figure 4.5A)
to detect Ste2p-monomer (53-55 kDa), Ste2p-dimer (106-110 kDa) and Ste2p-Gpa1p
cross-linked product (103-108 kDa). This allowed us to distinguish between Ste2p
homodimers and the crosslinked Ste2p-Gpa1p protein. Both antibodies revealed the same
crosslinking patterns for Ste2p and Gpa1p. However, because the Ste2p probe also
revealed homodimer and multiple-glycosylated proteins, these bands are much broader
and it is more difficult to discern the Ste2p-Gpa1p crosslinked product which is often
obscured by the Ste2p dimers (compare top and bottom gels). The Ste2p-Gpa1p crosslinked products were nearly completely reversed by treatment with 4% β-ME (see Figure
4.5, last three lanes for I249C-G470C), indicating that a disulfide bond connected the
hetero-dimeric Ste2p-Gpa1p. The fact that probing with both anti-Ste2p and anti-Gpa1p
132

(Figure 4.5B) resulted in the same signal on the gels indicates that the Santa Cruz
antibody can interact with the Ste2p-Gpa1p crosslinked product.
In the inactive state (without α-factor binding, Figure 4.4B α-factor “-“ lanes)
L248C in IL3 reacted with I469C in Gpa1p, whereas both L247C and I249C in IL3
reacted with N465C in Gpa1p (Figure 4.4, broken lines). Although previous studies
showed that I246C is highly accessible to a sulfhdryl reagent (37) this residue did not
react with the Gpa1p residues tested in this study. No detectable disulfide product was
observed for residues located in the middle of the IL3 loop or at the TM5 boundary in the
inactive conformation of Ste2p. In the ligand-bound, active conformation (Figure 4.5B
α-factor “+” lanes) both L228C (TM5) and I249C (TM6) reacted with G470C of Gpa1p.
S243C and L247C of the receptor reacted with K467C of Gpa1, whereas receptor I249C
reacted with I469C of Gpa1 (Figure 4.4, solid lines; Figure 4.5B). The Ste2p IL3 Cys
mutants (L228C, S243C, L247C, L248C and I249C) all displayed increased Ste2phomodimer formation when treated with Cu-P in the absence of α-factor (ligand) binding
to Ste2p (Figure 4.5A lanes labeled “– +”). In the presence of α-factor binding to Ste2p
(Figure 4.5A lanes labeled “+ +”) Ste2p-homodimer formation was reduced.
To test whether the IL3-Gpa1p interactions observed in the membrane samples
existed in the whole cell before membrane preparation, in vivo Cu-P treatment was
carried out on whole cells. For these experiments, cells co-expressing Ste2p-I249C and
Gpa1p mutants, N465C, L466C, K467C, K468C, I469C, G470C and I471C in the
presence or absence of α-factor were used. In this series of experiments N465, I469 and
G470 (indicated by asterisks) formed the heterodimers whereas L466, K467, K468 and
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I471 did not. These results (Figure 4.6) show that in vivo the interaction of receptor
mutant I249C with Gpa1p was similar to what was observed in membrane preparations.

Figure 4.6 Immunoblots of membranes from whole cells expressing Ste2p-I249C
together with various Gpa1p-Cys mutants (N465C-I471C) probed with anti-Gpa1p.
Samples were untreated (lanes -,-) or treated with Cu-P in absence (lanes -, +) or the
presence (lanes +, +) of α-factor. Membrane samples prepared from these cells were
resolved on 10% SDS-PAGE. The combinations that showed crosslinks are designated
with asterisks.
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Chapter 4
Discussion
We have used disulfide cross-linking to determine specific residue-to-residue
interactions between a yeast GPCR, Ste2p, in the active and inactive state and its cognate
Gα, Gpa1p, allowing identification of conformational changes involved in signal
transduction. Ste2p IL3 was observed to tolerate Cys substitutions well in our
experiments (37). The alignment of the C-terminus of Gpa1p with the last 11 amino acids
of transducin showed that in this region these two proteins are 50% identical and 70%
similar (Figure 4.2C). This portion of transducin was suggested to directly interact with
opsin and was used for co-crystallization with opsin to determine its binding to opsin
(38). Cysteine substitution of the individual eleven residues (I461-I471) of Gpa1p tested
in this study was well tolerated except for K468C, I469C and I471C which all resulted in
a partial pheromone response (Figure 4.2B), consistent with previous studies (17).
Signaling defects caused by mutation of the last five residues of Gpa1p have been
observed in most studies (14-16, 39) suggesting that these residues are indeed critical for
proper receptor coupling and Gpa1p activation. None of our mutations affected the
coupling of Gpa1p with the Gβγ protein subunits, implying that the carboxyl tail of
Gpa1p is essential for Ste2p coupling but not for interaction with Gβγ.
The crystal structure of opsin in its G protein-interacting conformation shows that
cytoplasmic ends of TM5 and TM6 provide a surface for hydrophobic interactions with
the C-terminus of transducin Gα (38). The disulfide cross-linking results from our study
indicated that analogously to the transducin-opsin interaction the C-terminus of Gpa1p
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interacts with TM5 and TM6 of Ste2p. In opsin, TM5 and TM6 are involved in van der
Waals interactions with the C-terminus of transducin, and a hydrogen bonded network
links the transducin and opsin residues (38). Cysteine disulfide cross-linking studies on
Cys-mutant residues in Ste2p IL3 suggested that α-factor binding to Ste2p resulted in
conformational changes involving the hydrophobic residues at the cytoplasmic ends of
TM5 and TM6 (Figure 4.5A). The close proximity of these hydrophobic residues (L228,
I247, L248, and L249) of Ste2p to the extreme C-terminus of Gpa1p indicates that these
residues provide a hydrophobic environment that favors the Gpa1p C-terminus
interaction. The crosslinking of S243C (Ste2p) with Q463C and K467C (Gpa1p) suggests
that the three polar residues are involved in a hydrogen bond bridged network. These
hydrogen-bonded bridges may be present during receptor activation, since these crosslinks were only observed in the active form of the receptor. However, this may be just
one of many networks, so the S243-Q463-K467 interaction may not be sufficient for full
activation of the receptor and/or Gpa1p.
In the classical GPCR-G protein ternary complex model the binding of an agonist
to the receptor induces the formation of a ternary complex consisting of a ligand, the
receptor, and a G protein, followed by the exchange of GDP for GTP. The complex
dissociates to Gα-GTP, Gβγ, and the receptor (9, 19). Although several models have been
proposed to explain the coupling between GPCRs and G proteins, the coupling mode is
still not well understood. The results from this study concur with the “precoupled” model
which suggests that the receptor and G protein are precoupled and may form a stable
complex regardless of the receptor activation state (40). The cross-linking of Ste2p Cys136

mutants to Gpa1p Cys-mutants in the presence and absence of ligand implies that the two
proteins are in close proximity both in the active and inactive receptor conformation.
These results provide physical evidence that the receptor-G protein complex exists prior
to activation and that it is not formed by random collision where the Gα couples with the
active receptor as suggested by the “collision coupling” model (41).
Activation of the Gα proteins by GPCRs has been observed to alter interactions of
residues in the GDP binding domains that open the GDP-binding cleft, allowing GDP
dissociation and the subsequent binding of GTP. Since the receptor binding domain of
Gα is on the opposite face of this protein from the GDP-binding cleft, the interaction with
the activated receptor must be transmitted to the GDP binding site by conformational
changes (18, 19, 21, 22, 41, 42). Recently, it has been shown that the exchange of GDP
for GTP in Gα proteins during receptor activation is induced by interactions of Gα with
the receptor regardless of the presence or absence Gβγ. Thus, interactions of receptor
with Gα proteins are the main requirements for the GDP/GTP exchange in Gα (9).
Conformational changes at the C-terminus of transducin Gα involving a helix-switch
were proposed based on structural and kinetic modeling. This helix-switch mechanism
suggests that the α5-helix (C-terminus) of transducin Gα rotates counter-clockwise
around its axis by 90° and tilts relative to the membrane by 42° (20) during activation.
Our disulfide crosslinking results suggest that two conformational changes affect
the interactions of residues at the Gpa1 carboxyl terminus with residues at the
cytoplasmic ends of TM5-TM6 of the receptor during Ste2p activation. The first
conformational change, which is a rotational movement of the C-terminus of Gpa1p,
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would be explained by the helix-switch mechanism model that is based on kinetic
modeling (20). This movement is supported by the switch of the disulfide crosslinks from
Gpa1p-N465C/Ste2p-L247C or Gpa1p-N465C/Ste2p-I249C in the inactive conformation
to Gpa1p-K467C/Ste2p-L247C or Gpa1p-I469C/Ste2p-I249C in the active conformation
(see Figure 4.7). Since the C-terminus of the Gpa1p is predicted to have a helical
structure similar to that of transducin (17) a rotation of the helix of ~120° is required to
switch a Gpa1p-N465C/Ste2p-L247C interaction to a Gpa1p-K467C/Ste2p-L247C
interaction. Based on our Ste2p crosslinking studies we have postulated that TM6
undergoes ~30° clockwise rotation upon ligand binding (Fig 4.5A), similar to what has
been suggested for TM6 of some mammalian GPCRs (2). Therefore, it is likely that
Gpa1p may not have to undergo the full ~120° rotation to switch the residue interactions;
an ~90° anti-clockwise rotation would suffice.
The second conformational change that would be consistent with our disulfide
crosslinking results is what we call the “withdrawal” movement. This movement is
necessary to explain the switch of the interactions between Gpa1p-N465/Ste2p-I249 in
the inactive conformation to Gpa1p-I469/Ste2p-I249 in the active conformation. This
switch requires the C-terminus (α5-helix) of Gpalp to move a distance that is
approximately the height of the pitch of an α-helix (~5.4 Å) and undergo a simultaneous
horizontal translation resulting in about 5 Å withdrawal from Ste2p. The concerted
rotational and translational movements are proposed to result in a shift of the Gpa1p α5helix from the TM6 cytoplasmic end towards the inner core of the receptor closer to TM5
and other TMs such as TM3 similar to the “translational” movement predicted by the
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helix-switch mechanism derived from kinetic modeling (20). The “withdrawal”
movement of Gpa1p α5-helix agrees with the α5-transmission rod concept of mammalian
Gα proteins in which the α5-helix acts as a transmission “piston rod” to propagate the
conformational changes from the receptor-G protein interface to the nucleotide binding
pocket (19, 20). We propose that the Gpa1p α5-helix (“rod”) rotates and moves away
from Ste2p. These movements may cause distortion at the β6-α5 loop of Gpa1p that
connects the C-terminus to the nucleotide-binding cleft, allowing GDP dissociation and
the subsequent exchange of GDP for GTP.

Figure 4.7 Proposed 3D model illustrating conformational changes in the
cytoplasmic ends of TM5-TM6 from Ste2p and the C-terminus of Gpa1p during
activation. Ste2p and Gpa1p residues are labeled green and blue, respectively. A
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(inactive state): The C-terminus of Gpa1p is suggested to be closer to TM6 than TM5 in
the inactive state. Upon α-factor binding changes occur at the cytoplasmic ends of TM5
and TM6. TM5 and TM6 are proposed to undergo rotation of ~30° in the anti-clockwise
and clockwise directions, respectively (indicated by green arrows) The C-terminus of
Gpa1p undergoes two possible changes (indicated by yellow arrows), an anti-clockwise
rotation of ~90° and a withdrawal of ~5.0 Å (horizontal and vertical shifts) from the inner
core of the receptor to the cytoplasmic end. B (active state): TM5 and TM6 are closer due
to a shift in TM6 towards TM5 as observed in other GPCRs (2, 43). The C-terminus of
Gpa1p is now closer to TM5 and withdrawn into the cytoplasmic surface of TM5-TM6.
There are possible H-bond links between S243 of Step and Q463/K467 of Gpa1p.

Several studies have shown that GPCR activation results in conformational
changes at the TM5-TM6 cytoplasmic ends that appear to be essential for G protein
activation in all GPCRs (2, 43-45). In this study we propose that the conformational
changes that occur at the TM5 and TM6 cytoplasmic ends induce rotational and
translational movements at the C-terminus of the Gpa1p that results in withdrawal of the
α5-helix of Gpa1p from Ste2p. The rotational and translational conformational changes
are consistent with a proposed model for the transducin-opsin system (20). Although,
further experimental work, such as identifying other residues in Ste2p and Gpa1p that are
involved in these movements will be needed to refine the mechanism of activation, the
information obtained in this study will serve as a platform for further understanding of
GPCR-G protein interactions in other systems.
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PART V
Crosslinking of an α-factor Analog [K0(BioACA), K7(DHPA), Nle12]αfactor (Bio-DHPA7 α-factor) into its G Protein-Coupled Receptor, Ste2p
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Part V presents collaborative work with Dr. Fred Naider’s laboratory at the City
University of New York, Staten Island. Li-Yin Huang performed most of the work,
George K. E. Umanah assisted with the biochemical studies, and the peptides used were
obtained from Dr. Naider’s laboratory.
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Abstract for Part V
Fundamental knowledge about how G protein-coupled receptors and their ligands
interact is important for understanding receptor-ligand binding and the development of
new drug discovery strategies. We have used periodate-mediated crosslinking and
matrix-assisted laser desorption/ionization

(MALDI)

spectrometric

analyses to

investigate the interaction of the center of the Saccharomyces cerevisiae tridecapeptide
pheromone, α-factor (WHWLQLKPGQPMY), and Ste2p, its cognate G protein-coupled
receptor.

Chemically synthesized [Lys0(BioACA),Lys7(DHPA),Nle12]α-factor with a

3,4-dihydroxyphenylacetyl (DHPA) attaching to lysine at position 7 (Bio-DHPA7 αfactor) was used to bind with Ste2p. Even though bio-DHPA7 α-factor exhibited about
40-fold decrease in binding affinity with Ste2p, it was able to activate growth arrest in
yeast cell. Bio-DHPA7 α- factor was crosslinked with Ste2p as demonstrated by Western
blot analysis using NeutrAvidin-HRP conjugates to detect Bio-DHPA7 α-factor and Ste2p
crosslinked product. Ste2p-ligand crosslinked complex was purified with His affinity
resin to pull down Ste2p that has a His tag at the C-terminus and with Avidin beads to
capture Bio-DHPA7 α- factor. After cyanogen bromide digestion, a crosslinked fragment
at the size of ~13 kDa was detected in Western blot probed with NeutrAvidin-HRP and
also in MALDI-TOF mass spectrum. The result of chemical crosslinking suggests that
Bio-DHPA7 α-factor interacts with transmembrane domain 2 to 3 flanking extracellular
loop 1 (TM2-EL1-TM3) region. Site-directed mutagenesis at this region is currently
being carried out to identify the exact crosslinked residue of Ste2p with DHPA7 α-factor.
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This is the first study to investigate the interacting residues between Ste2p and position 7
of α-factor.
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Chapter 1
Introduction
G protein-coupled receptors (GPCR) are composed of a superfamily of membrane
proteins that have a common structure of seven transmembrane domains. The
superfamily is divided into 6 groups (rhodopsin-like GPCRs, secretin receptor family
GPCRs, metabotropic glutamate GPCRs, fungal mating pheromone receptors, cyclic
AMP receptors, and Frizzled/Smoothened) based on the sequence homology and
functional similarity (1). The human genome encodes about 800-1000 GPCRs which
mediate a variety of signal transduction pathways (2), such as light, odorants, hormone,
and small molecule neurotransmitters. About 50% of the current medicines and 25% of
the top 100 best-selling drugs target GPCRs (3). Knowledge of GPCR structures,
including how they interact with their ligands and how they are activated, is an important
component aiding the development of novel drugs (4).
Understanding the interaction between ligands and their cognate GPCRs is
necessary for designing analogues useful in therapy of many human disorders. Using
Ste2p as a model to understand GPCR structure, the Konopka lab has shown by random
mutagenesis that residues near the extracellular ends of the transmembrane domains are
important for ligand binding and Ste2p activation (5, 6). According to the results of sitedirected mutagenesis in the Becker lab, several residues (S47, T48, T50, L102, F204,
N205, Y266, L276, and A280) at transmembrane domains of Ste2p have been identified
to be important for ligand binding and receptor activation (7, 8). In order to determine
direct contact points between α-factor and Ste2p, chemical (DOPA) and photoaffinity
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(Bpa) crosslinkers were used to label the ligand and capture the receptor. During α-factor
binding, a tryptophan at the N-terminus of α-factor is in close proximity to the Lys269 side
chain near the extracellular surface of the TM6-TM7 bundle of Ste2p (9, 10). A tyrosine
at the C-terminus of α-factor is likely to interact with Arg58 and Cys59 at transmembrane
domain 1 of Ste2p (11, 12).

A conclusion of these studies was that the chemical

crosslinker 3,4-dihydroxyphenylalanine (DOPA) is apparently more specific in
generating covalent linkage with specific residues of the receptor, which can be applied
to indetify the exact contact residues between DOPA-labeled peptide and the receptor.
Here, to indentify binding sites between α-factor and Ste2p, we used 3,4dihydroxyphenylacetyl (DHPA) as a crosslinker to label lysine residue in position 7 of αfactor to create [K0(BioACA), K7(DHPA), Nle12]α-factor (Bio-DHPA7-α-factor). DHPA
is similar to DOPA in that both contain the dihydroxyphenyl moiety involved in chemical
activation and crosslinking. DOPA was used as a replacement for an amino acid in αfactor in previous studies, wheareas DHPA was linked to the epsilon-amine of Lys7 of αfactor in the present study. Bio-DHPA7-α-factor was able to bind with Ste2p and activate
downstream cellular responses.

After His-tag (for purification of tagged Ste2p)

purification and cyanogen bromide digestion, avidin (to capture any biotinylated peptide)
purification was performed to capture crosslinked α-factor and Ste2p, and a 10-15 kDa
crosslinked fragment containing biotin and DHPA was identified. MALDI-TOF mass
spectrometric analysis confirmed the digested fragment, which suggests that Bio-DHPA7α-factor formed a covalent cross-linkage with the residue at the boundary of
transmembrane 2 and 3 flanking extracellular loop 1 (TM2-EL1-TM3).
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Chapter 2
Materials and Methods
Media, Reagents, Strains and Plasmids
Saccharomyces cerevisiae strain LM102 [MATa, bar1, his4, leu2, trp1, met1,
ura3, FUS1-lacZ::URA3, ste2Δ (13)] was used for growth arrest and binding assays and
protease deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52
ste2::KanR (14)] was used for protein isolation and immunoblot analysis. The plasmid
pBEC1 containing C-terminal FLAG and His tagged STE2 (13) was transformed by the
method of Geitz (15) into LM102 and BJS21 cells. Transformants were selected by
growth on yeast media (16) lacking tryptophan (designated as MLT) to maintain selection
for the plasmid. The Cells were cultured in MLT and grown to mid-log phase at 30°C
with shaking (200 rpm) for all assays. The tridecapeptide pheromone α-factor analog
[(BioACA)-Lys0 (3,4-dihydroxyphenylacetyl)-Lys7, Nle12] (designated Bio-DHPA7 αfactor) was synthesized using automated solid-phase peptide synthesis and purified by
reverse-phase high-performance liquid chromatography (HPLC) to greater than 99%
homogeneity. All protected amino reagents were purchased from Advanced Chem Tech
(Louisville, KY) and all solvents and reagents were of the highest purity available.

Mass Spectrometric Analysis of Peptides
For matrix-assisted laser-desorption ionization (MALDI) analysis the peptides
were resuspended in 50:50 water-acetonitrile with 0.1% trifluoroacetic acid (TFA) at a
final concentration of 0.1μg/μl. A 20mg/ml α-cyano-4-hydroxy-trans-cinnamic acid [(α154

ACHA), Sigma/Aldrich Chemical Company, St. Louis, MO] matrix was prepared by
dissolving recrystallized α-ACHA in 50:50 water-acetonitrile with 0.1% TFA. An equal
volume (0.5 μl) of peptide solution was mixed with matrix before spotting on the MALDI
plate. The MADLI-TOF spectra were acquired on a Bruker Daltonics (Boston, MA)
Microflex using the reflector methods.

Growth Arrest Assays
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at
30ºC in MLT, harvested, washed three times with water and resuspended at a final
concentration of 5 x 106 cells/ml (14). Cells (1 ml) were combined with 3.5 ml agar noble
(1.1%) and poured as a top agar lawn onto MLT medium agar plate. Filter disks (BD,
Franklin Lakes, NJ) impregnated with α-factor or various α-factor analogs were placed
on the top agar. The plates were incubated at 30ºC for 18 hours and then observed for
clear halos around the discs. The experiment was repeated at least three times.

Binding Competition Assays
This assay was performed using LM102 cells expressing C-terminal FLAG and
His tagged Ste2p. Tritiated [3H]-α-factor (10.2 Ci/mmol, 12 μM) prepared as previously
described (14, 17) was used in competition binding assays on whole cells. The cells were
grown at 30ºC in MLT, harvested, washed three times with YM1 [0.5 M potassium
phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium
fluoride, and 1% BSA] and adjusted to a final concentration of 2 x 107 cells per ml in
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YM1 plus protease inhibitors [YM1i] (18). For competition binding studies, cells (600 μl)
were combined with 150 μl of ice cold YM1i supplemented with 6 nM [3H]α-factor in the
presence or absence α-factor analogs and incubated at room temperature for 30 minutes.
The final concentrations of α-factor analogs ranged from 0.5 x 10-10 to 1 x 10-6 M. After
incubation, triplicate aliquots of 200 μl samples were filtered and washed over glass fiber
filter mats using the Standard Cell Harvester (Skatron Instruments, Sterling, VA) and
placed in scintillation vials. The radioactivity [3H] on the filter was counted by liquid
scintillation spectroscopy. The binding data were analyzed by non-linear regression
analysis for one-site competition binding using Prism software (GraphPad Software, San
Diego, CA) to determine the binding affinity (Kd) for each peptide. The Ki values were
calculated by using the equation of Cheng and Prusoff, where Ki = EC50 / (1 + [ligand] /
Kd) (7).

DHPA Chemical Crosslinking
BJS21 cells expressing C-terminal FLAG and His tagged Ste2p were grown and
total cell membranes were isolated as previously described (14). Protein concentration
was determined by BioRad (BioRad, Hercules, CA) protein assay (13). The membranes
were re-suspended in NEBuffer [20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl,
12.5 mM EDTA, 0.5 mM DTT (19)] incubated with Bio-DHPA7 α-factor analog (1 μM)
in the presence or absence of 100 μM α-factor (WHWLQLKPGQPNle12Y) for 120
minutes at 4°C. For periodate mediated crosslinking, a final concentration of 1.0 mM
NaIO4 was added to the mixture and incubated for 2 minutes. A final concentration of
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100 mM DTT (1,4-Dithiothreitol) was used to quench the reaction (19). The cross-linked
membranes

were

washed

three

times

with

CAPS

buffer

[Ncyclohexyl-3-

aminopropanesulfonic acid (Sigma, St. Louis, MO.), 10 mM, pH 10] by centrifugation to
remove non-bound Bio-DHPA7 α-factor. The washed crosslinked samples were
fractionated by SDS-PAGE and then transferred to immunoblots. The blots were probed
with an antibody directed against the FLAG tag at C-terminal of Ste2p and with
NeutrAvidin-HRP conjugate (Pierce, Rockford, IL) to detect biotin tag on Bio-DHPA7
pheromone covalently linked to Ste2p. The signal generated were analyzed using
Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation system
(BioRad, Hercules, CA).

Purification of Intact Crosslinked Ste2p
Crosslinked Ste2p was enriched using His-SelectTM HC-Nickel affinity gel
(Sigma/Aldrich Chemical Co., St. Louis, MO) following the manufacturer’s directions.
Approximately 10 mg cell membrane containing crosslinked Ste2p were resuspended in
ice-cold solubilization buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X100) with protease inhibitors (PMSF, pepstatin A and leupeptin) and incubated overnight
at 4ºC with end-over-end mixing, then centrifuged at 15,000 x g for 30 minutes to remove
non-soluble material. The solubilized proteins were then mixed with His-Nickel resin and
incubated at 4ºC with end-over-end mixing for 1 hour. The resin was collected by
centrifugation at low speed (500 x g, 1 minute) and resuspended and collected four times
in wash buffer (50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, and 5 mM
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imidazole). Ste2p was eluted by resuspending the resin in 1 ml ice-cold elution buffer (50
mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, and 250 mM imidazole) and
incubated at 4ºC with end-over-end mixing for 10 minutes. The resin was pelleted by
centrifugation (2000 x g, 1 minute) and the supernatant, containing eluted Ste2p,
transferred to a fresh tube. The samples were analyzed by immunoblotting using an
antibody directed against the FLAG tag at C-terminal of Ste2p and with NeutravidinHRP conjugate to detect the biotin tag on the DHPA peptide covalently linked to Ste2p.

Digestion of Crosslinked Ste2p
Crosslinked Ste2p samples eluted from the His-Nickel resin were digested with
cyanogen bromide (CNBr). The eluted samples containing Ste2p (~20 μg) were dried by
vacuum centrifugation (Thermo Scientific, Waltham, MA) then dissolved in 100%
trifluoroacetic acid (TFA) containing 10 mg/ml CNBr. Deionized distilled water
(ddH2O) was then added to adjust the final TFA concentration to 80%, and the samples
were incubated at 37°C in the dark for 18 hours (14, 20). The samples were dried by
vacuum centrifugation and washed three times with ddH2O, and then 1 M Tris-HCl (pH
8.0) was added to neutralize the acidic mixture.

Purification of Crosslinked Ste2p Fragments
After CNBr digestion, crosslinked Ste2p fragments were resuspended in PBS
buffer (0.1 M sodium phosphate, 0.15 M sodium chloride; pH 7.0), mixed with
NeutrAvidin resin (Pierce Thermo Scientific, Rockford, IL,USA) and incubated for 6
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hours at 4ºC with end-over-end mixing (21). The resin was collected by centrifugation at
low speed (1000 x g, 1 minute) and washed four times in PBS buffer. Crosslinked Ste2p
fragments were eluted by resuspending the resin in 200 μl ice cold elution buffer (0.1 M
glycine, pH 2.5) and incubating at 4ºC with end-over-end mixing for 5 minutes. The resin
was pelleted by centrifugation (2000 x g, 1 minute) and the supernatant, containing the
eluted crosslinked Ste2p fragments, transferred to a fresh tube containing 20 μl of TBS
(0.5 M Tris HCl, pH 7.4, 1.5 M NaCl).

MALDI-TOF Analysis of Crosslinked Peptides
The eluted samples from the avidin resin were further washed and concentrated
using a pipette with C18 chromatographic media (ZipTipC18 pipette tips; Millipore
Corporation, Billerica, MA) following the manufacturer’s directions and resuspended in
60% acetonitrile 40% water (0.1% TFA). For MALDI-TOF analysis α-CHCA [20 mg/ml
(in 50:50 acetoneisopropanol)] was used as the matrix. The samples (0.5 μl), were either
mixed with 0.5 μL of matrix before spotting on the target or 1.0 μl of matrix was spotted
and allowed to dry before applying 1.0 μL of samples (14). MALDI-TOF spectra were
acquired on a Bruker Daltonics Microflex using the reflector method. Masses were
calculated using PROWL peptide mass prediction tools (22) and also based on the
chemistry of the DHPA cross-linking (19).
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Chapter 3
Results
Synthesis and Characterization of Bio-DHPA7 α-factor

Figure 5.1 Structures of α-factor and Bio-DHPA7 analogue. Biotin (Bio) is conjugated
through its carboxyl group to the ε–amine of Lys1 using aminocaproate as a linker and
3,4-dihydroxyphenylacetyl (DHPA) is attached to Lys7 residue to form [K0(BioACA),
K7(DHPA), Nle12]α-factor (Bio-DHPA7 α-factor) analogue of α-factor.
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The synthesis of α-factor analogs containing 3,4-dihydroxyphenylacetyl (DHPA)
was carried out by automated solid phase synthesis using standard coupling and
deprotection protocols (10, 12). Fmoc protected peptide was obtained in high yield and
purity and was used in the hydroxysuccinimiude mediated addition of biotinylamido
caproate (9). The final peptides used in bioassays and cross-linking studies were virtually
homogeneous as judged by gradient HPLC and had the expected molecular weights. The
structures of α-factor and Bio-DHPA7 analogue are shown in Figure 5.1; MALDI-TOF
analyses and MS/MS spectra are shown in Figure 5.2. Observed mass of the peptides as
determined by MALDI-TOF were similar to masses predicted by the PROWL peptide
mass prediction tools (23).

Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of αfactor and Bio-DHPA7 analog. (Continued on next page)
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Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of αfactor and Bio-DHPA7 analog. Panel A (left): Observed masses of the peptides
determined by MALDI-TOF. Panel B (right): MALDI post-source decay spectra.
(Continued on next page)
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Figure 5.2 Mass spectrometric analysis and MALDI post-source decay spectra of αfactor and Bio-DHPA7 analog. Panel A (left): Observed masses of the peptides as
determined by MALDI-TOF were similar to masses predicted by PROWL peptide mass
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prediction tools (22): [Nle12]α-factor 1665.96 Da, [K0, Nle12]α-factor 1794.15 Da,
[K0(BioACA), Nle12]α-factor 2133.61 Da, [K0, K7(DHPA), Nle12]α-factor 1944.34 Da,
and [K0(BioACA), K7(DHPA), Nle12]α-factor 2283.74 Da. Panel B (right): One-letter
inserts are abbreviations of amino acid residues. Peptides and spectra are labeled with
identified y and b ion types.

A total of four α-factor analogues were synthesized: [K0, Nle12]α-factor has a
lysine added at the N-terminus of α-factor (position 0), [K0(BioACA), Nle12]α-factor has
a biotin added to the lysine at position 0, [K0, K7(DHPA), Nle12]α-factor has lysine at
position 0 and dihydroxyphenylacetyl (DHPA) attached to the lysine at position 7, and
[K0(BioACA), K7(DHPA), Nle12]α-factor (Bio-DHPA7 α-factor) has biotin labeling on
the lysine at position 0 and DHPA attached to the lysine at position 7. MALDI-TOF Mass
spectrometry was used to determine molecular mass of α-factor analogues (Figure 5.2).
According to mass spectra, [K0, Nle12]α-factor showed a monoisotopic peak at 1793.662
Da (predicted 1794.15 Da), [K0(BioACA), Nle12]α-factor showed a peak at 2132.381 Da
(predicted 2133.61 Da), [K0, K7(DHPA), Nle12]α-factor showed a peak at 1943.477 Da
(predicted 1944.34 Da), and [K0(BioACA), K7(DHPA), Nle12]α-factor showed a peak at
2282.032 Da (predicted 2283.74 Da). Some of the peptides showed more than one peak,
which might be due to impurities in the samples. FAST program in MALDI-TOF was
used for further fragmentation and detailed mapping of peptide sequence. Ionized
fragments matched the sequence of α-factor analogues (Figure 5.2).
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Binding and Bioactivity of Bio-DHPA7 α-factor

Figure 5.3 Binding and bioactivity of α-factor analogues. A: Binding ability of the
peptides was determined by competition binding with [3H]-labelled α-factor for Ste2p. B:
Growth arrest assay was used to check activation of Ste2p signaling pathway.

A competition binding assay was performed to determine the binding affinity of
α-factor analogues (Figure 5.3A). The modification and addition of lysine, biotin, and
DHPA on -factor decreased binding affinity of the peptides so a shift toward higher
concentrations was observed for competition, due to lower binding efficacy of BioDHPA7 α-factor. The growth arrest assay was performed to check biological activity of
α-factor analogues. As shown in Figure 5.3B, Bio-DHPA7 α-factor formed smaller halos
when compared with α-factor. When the concentration of peptide was increased by 4
fold, distinct halos were observed. When compared with -factor, attachment of DHPA
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at Lys7 decreased binding affinity 30 fold and biological activity by 50%; whereas the
addition of biotin decreased binding affinity 18 fold and biological activity by 75%.
Through competition binding and halo assay, we know that Bio-DHPA7 α-factor is able
to bind and activate Ste2p signaling pathway, even though the binding affinity is lower
than that of -factor.

Bio-DHPA7 α-factor Crosslink into Ste2p

Figure 5.4 Western blot analysis of Bio-DHPA7 α-factor crosslinked with Ste2p.
Crosslinked product of Bio-DHPA7 α-factor and Ste2p appeared before (A) and after (B)
His-Nickle purification on western blots probed with NeutrAvidin-HRP conjugate (upper
panels). K0(BioACA) α-factor was used as a negative control for crosslinking; an excess
amount of α-factor was used to compete with the crosslinking of Bio-DHPA7 α-factor.

166

Western blots at lower panels were probed with FLAG antibody to show total loading of
Ste2p.

Since Bio-DHPA7 α-factor was able to bind Ste2p and activate the signaling
pathway, chemical crosslinking with NaIO4 was carried out in the presence of DHPA
peptide (10 µM) and Ste2p membrane protein (500 µg). As shown in Figure 5.4A, BioDHPA7 α-factor was crosslinked with Ste2p, and the signal was decreased in the presence
of excess α-factor (1 mM), which means the crosslinking is specific for binding pocket of
Ste2p. Notably, when Bio-DHPA7 α-factor was used as a negative control for
crosslinking, it showed no signal in NeutrAvidin Western blot, which proves that NaIO4
crosslinking is very specific to DHPA side chain. After crosslinked samples were purified
with His-Nickel resin, background signal was reduced and Ste2p-DHPA α-factor
crosslink became more distinct (Figure 5.4B). Non-specific background signal can be
further reduced by using less peptide in the crosslinking reaction or by more diluted
primary antibody (NeutrAvidin-HRP) for immunoblot analysis (data not shown).
In order to identify a specific Ste2p residue that crosslinked with Bio-DHPA7 αfactor, binding with Bio-DHPA7 α-factor (20 µM) on a large scale membrane preparation
(10 mg) was performed to enrich crosslinked product for His-Nickel and NeutrAvidin
purification and cyanogen bromide (CNBr) digestion. Crosslinked product was purified
separately with His-Nickel resin to pull down Ste2p by its His tag at the C-terminal and
with NeutrAvidin resin to capture Bio-DHPA7 α-factor. After His-Nickel purification, a
distinct band representing Ste2p appeared at approximate 55 kDa position in a Western
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blot probed with FLAG antibody (Figure 5.5). The same band at 55 kDa also showed up
when the Western blot was probed with NeutrAvidin-HRP conjugate, which suggested
that the band is a crosslinked product of Ste2p and Bio-DHPA7 α-factor. Furthermore,
after NeutrAvidin purification, a distinct band also showed up at the size corresponding
to Ste2p when Western blot was probed with NeutrAvidin. The same band appeared in
anti-FLAG Western blot as well, which indicated the crosslinked product of Bio-DHPA7
α-factor and Ste2p was purified.

Figure 5.5 Western blot analysis of Bio-DHPA7 α-factor and Ste2p crosslink after
His-Nickel and NeutrAvidin purification. After treatment with 1 mM NaIO4,
crosslinked samples were lysed and purified with His-Nickel and NeutrAvidin resins.
Eluted protein were separated in SDS-PAGE for Western blot analysis probed with
NeutrAvidin-HRP conjugate and FLAG antibody.
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Figure 5.6 Western blot analysis of purified Bio-DHPA7 α-factor and Ste2p
crosslink after cyanogen bromide digestion. His-Nickel and NeutrAvidin purified BioDHPA7 α-factor and Ste2p crosslink was subjected to cyanogen bromide digestion.
Digested peptide was then separated in SDS-PAGE for Western blot analysis and probed
with NeutrAvidin-HRP (A). Cyanogen bromide cut at methionine residues of Ste2p and
generates eight digested fragments (B).

After His-Nickel and NeutrAvidin purification, cyanogen bromide (CNBr) was
then used to digest the crosslinked product of Bio-DHPA7 α-factor and Ste2p. CNBr
hydrolyzes peptide bonds at the C-terminus of methionine residues and generated eight
digested fragments of Ste2p. Digested sample was then separated in SDS-PAGE for
Western blot analysis. After probing with NeutrAvidin-HRP (Figure 5.6A), a crosslinked
fragment appeared at the size between 10-15 kDa. Therefore, according to the predicted
digestion of Ste2p (Figure 5.6B), transmembrane domain 2-extracellular loop 1transmembrane domain 3 (TM2-EL1-TM3) (~10.6 kDa) is very likely to be the fragment
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that

interacts

with

Bio-DHPA7

α-factor

(~2

kDa).

Matrix-assisted

laser

desorption/ionization (MALDI) mass spectrometric analysis was performed to ionize the
fragment and generate a monoisotopic spectrum (Figure 5.7). A peak appeared at massto-charge ratio (m/z) of 12404.046, which is close to the expected size of the crosslinked
fragment.

Figure 5.7 Mass spectrum of MALDI-TOF analysis for crosslinked fragment of BioDHPA7 α-factor and Ste2p. Crosslinked product of Bio-DHPA7 α-factor and Ste2p was
purified with His-Nickel and NeutrAvidin resins and digested with cyanogen bromide.
Expected molecular mass is at 12895.232 Da and the monoisotopic peak appeared at
12404.046 (m/z).
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Because DHPA forms crosslinked complex with certain favored amino acids
(cysteine, lysine, histidine) when they are in close proximity, according to the protein
sequence of Ste2p, there are six residues (K77, H94, K100, H126, K151, and K160) in TM2EL1-TM3 that would be favored to interact with Bio-DHPA7 α-factor (Figure 5.8).
Among the six residues, H94, K100, and H126 are more likely to be near the binding pocket
of Ste2p because they are either close to the transmembrane domain or in the
extracellular loop. Therefore, site-directed mutagenesis of K100 and H126 was carried out.
We constructed two alanine mutants (K100A and H126A). The results indicated,
however, that these mutants still crosslinked with Bio-DHPA7 α-factor. Mutation at the
other residues is required to determine the exact binding site and tandem mass
spectrometry (MS/MS) may be a better alternative to identify crosslinked residue.
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Figure 5.8 Diagram of Ste2p. The residues from intracellular loop 1 (IL1) to
intracellular loop 2 (IL2) was highlighted. Six residues (K77, H94, K100, H126, K151, and
K160) in TM2-EL1-TM3 region are the candidates to interact with Bio-DHPA7 α-factor.

Labeling the ligand with DOPA (3,4-dihydroxyphenylalanine) to serve as a
crosslinker has been used to identify interacting residues of Ste2p with the N-terminal
and C-terminal ends of α-factor (10, 12). This is the first study to use a DOPA-like
compound, DHPA (3,4-dihydroxyphenylacetyl), as a crosslinker to investigate whether
lysine at the center (seventh amino acid) of the ligand binds with Ste2p. DOPA and
DHPA share the dihydroxyl ring, which can be oxidized by NaIO4 to form an ortho172

quinone intermediate. This activated product has the tendency to react with the side chain
of cysteine, histidine, and lysine (24) and therefore can be used to map peptide ligandprotein interaction. According to the results presented, adding DHPA to the epsilonamine of the lysine residue at position 7 of α-factor decreased binding affinity of the
peptide about 30 fold. However, with an adequate amount of Bio-DHPA7 α-factor present
in the binding reaction, it was able to compete with the binding of α-factor, and BioDHPA7 α-factor triggered downstream growth arrest activity, even though the halos were
smaller than those formed in the presence of α-factor. Therefore, we conclude that BioDHPA7 α-factor is likely to interact with the same binding pocket of Ste2p because of its
ability to compete with α-factor and transduce a downstream signal.
After crosslinking, His-Nickel and NeutrAvidin purification enriched for the
Ste2p-DHPA crosslinked product. Cyanogen bromide hydrolysis indicated a crosslinked
band at 10-15 kDa as detected in a Western blot probed with NeutrAvidin, which
corresponded to the TM2-EL1-TM3 fragment (T72-M165, ~10.6 kDa). The monoisotopic
mass of TM2-EL1-TM3 fragment after CNBr digestion is expected to be 10613.811 Da
and Bio-DHPA7 α-factor is 2282.032 Da. The expected size of TM2-EL1-TM3 and BioDHPA7 α-factor complex was expected to be about 12895 Da, but the measured peak
after MALDI-TOF fractionation indicated a molecular of 12404.046 m/z. The reason for
the mass difference of ~491 Da needs to be further studied. The mass spectrum from
MALDI-TOF analysis (Figure 5.7) showed the monoisotopic peak at 12404.046 (m/z)
within a broad band ranging from 12000 to 13000 (m/z). It is possible that the true
crosslinked peak was overshadowed by the broad band.
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Chapter 1
General Conclusions and Discussion
Unnatural Amino Acid Replacement in a Yeast G Protein-Coupled Receptor in its
Native Environment (Incorporation of p-benzoyl-L-phenylalanine, Bpa, into Ste2p)
In this study, we demonstrated site-specific incorporation of Bpa into Ste2p, a
yeast GPCR, by using an orthologous tRNA/aminoacyl-tRNA synthetase pair. Eight
mutant STE2 constructs (F55TAG, S107TAG, G115TAG, V127TAG, G188TAG, Y193TAG,
F204TAG, and Y266TAG) were created by engineering the amber TAG stop codon at
specific sites within the open-reading frame. An advantage of using the orthologous
tRNA/aminoacyl-tRNA synthetase pair to incorporate Bpa into Ste2p in the yeast cell is
that the GPCR remains in its native environment and is therefore able to interact with
downstream effector molecules, such as the heterotrimeric G proteins, thus allowing
assessment of both ligand binding and signal transduction pathway. The incorporation
was verified by mass spectrometry, and our result indicates that, once incorporated, the
photo-reactive Bpa in Ste2p in certain positions can be used to crosslink with the ligand.
We demonstrated that Bpa incorporated into both the F55 (located in transmembrane
domain 1, TM1) and Y193 (located in extracellular loop 2, EL2) receptors was able to
capture biotinylated α-factor. Photo-reactive crosslinking can be largely competed out by
the presence of excess nonbiotinylated α-factor. While F55 is positioned in the binding
pocket of the receptor and was expected to interact with the pheromone (1), the ability of
Bpa in Y193 to capture the ligand suggests a possible role for EL2 in ligand binding. We
also used a novel method to supply Bpa to yeast cells via the di/tripeptide transport
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system that is common to many eukaryotes (2, 3). Expression of the Y193TAG receptor as
well as the F55TAG and G188TAG receptors was noticeably enhanced when the cells were
grown in the presence of Met-Bpa at 0.1-0.5 mM when compared to Bpa. Because
peptide transporters are ubiquitous in living cells (3), this method can be used to increase
the delivery of unnatural amino acids and extend this approach to amino acids that are
impermeable to yeast cells. These results set a stage for the use of unnatural amino acid
technology in exploring the structure and interaction of integral membrane proteins in
their native environment.

Changes in Conformation at the Cytoplasmic Ends of the Fifth and Sixth
Transmembrane Helices of a Yeast G Protein-Coupled Rreceptor in Response to
Ligand Binding (Cysteine mutations for disulfide crosslinking of residues in Ste2p)
The third intracellular loop of Ste2p has been shown to play an important role in
signal transduction and is involved in Gpa1p (Gα protein in S. cerevisiae) activation (46). Transmembrane domain 5 (TM5) and 6 (TM6) that flank the intracellular loop 3 (IL3)
have also been shown to interact with each other and have been suggested to play a
critical role in signaling (7). In this study, we have used cysteine mutation and disulfide
crosslinking analysis to determine conformational changes of residues in IL3 and the
ends of TM5 and TM6 transmembrane domains of Ste2p during ligand-induced
activation. The result showed strong dimer formation occurred in the IL3 Cys mutants,
which is consistent with the conclusion in rhodopsin where IL3 was identified to play a
role in receptor oligomerization (8-10). Dimer formations observed in our study were
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also detected in intact cells, indicating that the disulfide bond formation between the two
monomers of Ste2p occurs in the native environment of the receptor. The pattern of
disulfide formation in our study, with R233C, L236C, and K239C mutant receptors
having the highest percent of disulfide formation, suggests that the residues in IL3 (R233–
Q240) may form a 310 helix. Disulfide formation involving residues in the middle of IL3
was not sensitive to ligand binding, implying that residues in the IL3 loop do not change
conformation or availability during receptor activation. In contrast, addition of α-factor
affected the levels of disulfide formation in Cys-substituted receptors at the boundaries of
TM5 and TM6, suggesting that activation of Ste2p involved ligand-induced
conformational changes in the cytoplasmic ends of TM5 and TM6. A proposed model
according to our experimental data would be: upon ligand binding the two dimer
interfaces (TM5/TM5 and TM6/TM6) of Ste2p at the cytoplasmic end shift away from
each other or become less flexible so they cannot form the disulfide bond linkage. The
reduction of dimer at the cytoplasmic end of TM5 and TM6 was not observed in the
presence of an α-factor antagonist, suggesting that antagonist binding to Ste2p does not
induce the conformational change or alter the flexibility at the TM5 and TM6. In
conclusion, we showed for the first time changes in receptor conformation or flexibility
that influence disulfide formation in the region of IL3 of Ste2p close to the TM5 and
TM6 boundaries. The hydrophilic residues located in the middle of the IL3 loop (R231–
Q240) do not change conformation/availability during receptor activation, whereas many
hydrophobic residues at the TM5 and TM6 cytoplasmic ends do. These conformational
changes require ligand-induced activation of Ste2p and appear to depend on Ste2p–Gα
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protein interactions. The pattern of disulfide formation observed is consistent with a
310 helical structure in the center of IL3 and suggests that the IL3 loop of two Ste2p
subunits remain close in proximity both in the active and inactive states of the receptors.
Since Ste2p has been shown to have structure–function relationships similar to the
physiologically and pharmacologically important rhodopsin-like GPCR family (11), the
role of IL3 observed in this study has implications not only for Ste2p but also other
GPCR systems.

Residue-to-Residue Interactions between a G Protein-Coupled Receptor (GPCR)
and its Gα Protein in the Saccharomyces cerevisiae Model System (Cysteine
mutation for disulfide crosslinking of residues in Ste2p and Gpa1p)
Several studies have shown that GPCR activation results in conformational
changes at the TM5-TM6 cytoplasmic ends that appear to be essential for G protein
activation in all GPCRs (12-15). Studies on the interactions between Ste2p and Gpa1p, its
Gα protein, indicate that the Ste2p third intracellular loop (IL3) is involved in Gpa1p
activation (4-6, 16). Like other Gα proteins in mammals, the region of Gpa1p that has
been most commonly predicted to interact with Ste2p is the C-terminus (17-19). We have
applied cysteine mutation and disulfide crosslinking to determine specific residue-toresidue interactions between Ste2p and Gpa1p. Using combinatorial expression and assay
of 242 Ste2p and Gpa1p cysteine mutants, five Ste2p residues (L228C, S243C, L247C,
L248C, and I249C) located at the cytoplasmic ends of the transmembrane domain 5
(TM5) and 6 (TM6) were identified to interact with five residues (Q463C, N465C,
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K467C, I469C, and G470C) of the C-terminus of Gpa1p. The patterns of Gpa1p
interaction with Ste2p in the presence and absence of α-factor suggest that the C-terminus
of Gpa1p is closer to TM6 than TM5 in the inactive state of Ste2p. Upon α-factor
binding, TM5 and TM6 of Ste2p should undergo ~30° of rotation in counterclockwise
and clockwise directions, respectively, and TM6 would shift closer to TM5 as observed
in other GPCRs (2, 43). The C-terminus of Gpa1p also undergoes two possible changes,
rotational and “withdrawal” movements that are required for proper Ste2p coupling and
Gpa1p activation. A rotation of the helix (C-terminus) of Gpa1p for ~120° is required for
the change of interaction from Ste2p-L247C/Gpa1p-N465C in the inactive state to Ste2p247C/Gpa1p-467C in the active state. Since TM6 is likely to undergo ~30° clockwise
rotation upon ligand binding , Gpa1p may not have to rotate a full ~120° after activation;
a ~90° of counterclockwise rotation in Gpa1p would be sufficient. The second
conformational change consistent with our disulfide crosslinking results is what we call
the “withdrawal” movement. There is a switch of interaction from Ste2p-I249C/Gpa1pN465C in the inactive state to Ste2p-I249C/Gpa1p I469C in the active state. This switch
requires the C-terminus of Gpa1p to move a distance that is approximately the height of
an α-helix (~5.4 Å) and undergo a horizontal translation, which may result in about 5 Å
withdrawal movement of Gpa1p from Ste2p after activation. Concerted rotational and
translational movements between Ste2p and Gpa1p upon ligand binding are proposed
whereby the C-terminus of Gpa1p shifts from the TM6 cytoplasmic end towards the inner
core of the receptor closer to TM5 and other TMs, such as TM3. Overall, we have
proposed the conformational changes in TM5 and TM6 of Ste2p upon ligand binding,
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which induces rotational and translational withdrawal movements at the C-terminus of
the Gpa1p. This proposed model is similar to the “translational” movement predicted by
the helix-switch mechanism derived from kinetic modeling (20). This study is the first to
identify specific residue-to-residue interactions between a GPCR and its cognate Gα
protein in its active and inactive states.

Crosslinking of an α-factor Analog [K0(BioACA), K7(DHPA), Nle12]α-factor (BioDHPA7-α-factor) into its G Protein-Coupled Receptor, Ste2p (Incorporation of 3,4dihydroxyphenylacetyl, DHPA, into α-factor and its crosslinking to Ste2p)
Besides utilizing photo-reactive crosslinking with Bpa-labeled ligand (1, 21) to
probe the binding domain of Ste2p, we have also applied a periodate-mediated
crosslinking with 3,4-dihydroxyphenylalanine (DOPA) labeled α-factor to identify
specific interacting residues in Ste2p (22, 23). In this study, we used a DOPA-like
compound, DHPA (3,4-dihydroxyphenylacetyl), as a crosslinker to investigate where
lysine at the center (seventh amino acid) of α-factor binds with Ste2p. DOPA and DHPA
share the dihydroxyl ring, which can be oxidized by NaIO4 to form an ortho-quinone
intermediate. This activated product has the tendency to interact with the side chains of
cysteine, histidine, and lysine (24) and therefore can be used to map peptide ligandprotein interactions. Chemically synthesized [K0(BioACA), K7(DHPA), Nle12]α-factor
(Bio-DHPA7 α-factor) with a DHPA attached to lysine at position 7 and biotin attached to
lysine added to the amino-terminus of α-factor was used to bind to Ste2p. Even though
attachment of DHPA at Lys7 decreased binding affinity about 30 fold, it was able to
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activate growth arrest in the yeast cell. With an adequate amount of Bio-DHPA7 α-factor
present in the binding reaction, it was able to compete with the binding with α-factor.
Therefore, we conclude that Bio-DHPA7 α-factor is likely to interact with the same or
similar pocket of Ste2p because of its ability to compete with α-factor and transduce a
downstream signal. Bio-DHPA7-α-factor was crosslinked into Ste2p as demonstrated by a
Western blot probed with NeutrAvidin-HRP conjugates to detect Bio-DHPA7 and Ste2p
crosslinked product. The Ste2p-ligand crosslinked complex was then purified with HisNickel to pull down Ste2p with its His tag at the C-terminus and with avidin beads to
capture biotin-labeled ligand and its crosslinked products. Cyanogen bromide digestion
was applied and a crosslinked fragment at the size of ~13 kDa was detected in the
Western blot probed with NeutrAvidin-HRP and also by MALDI-TOF mass
spectrometry. Due to the size of the crosslinked fragment we suggest that Bio-DHPA7 αfactor was crosslinked with transmembrane domain 2 to 3 (T72-M165, ~10.6 kDa) flanking
extracellular loop 1 (TM2-EL1-TM3) region. Site-directed mutagenesis and tandem mass
spectrometry of this region are currently being carried out in order to identify the exact
crosslinked residue of Ste2p with Bio-DHPA7 α-factor. This study is the first to
investigate the interacting residues between Ste2p and position 7 of α-factor. By
determination of the Ste2p residues that interact with the first, last, and middle residues of
the ligand, we expect to be able to build a better model for the interaction pocket of Ste2p
and α-factor.
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Summary for the structure and activation of Ste2p
The inactive, or resting, form of Ste2p serves as a restraint function to keep G
proteins in the basal state and to prevent activation of pheromone response signaling in
the absence of α-factor. Several pairs of residue interactions within the transmembrane
domains (N84-Q149, V223-L247, Q253-S288, Q253-S292, and N205-Y266) (25, 26) have been
identified to maintain inactive state of Ste2p. In addition, site-directed mutagenesis (2629) has also revealed that certain residues (S141, I153, I169, and L222, P258, A281, and T282)
are essential to limit constitutive activity of Ste2p. These residues and interactions among
transmembrane domains are crucial to hold the inactive confromation of Ste2p in order to
avoid unnecessay cellular response.
When the ligand α-factor appears, suggested by mutagenesis studies of Ste2p (2934), many residues (S47, T48, T50, F55, F99, Y101, L102, Y128, F204, N205, Y266, D275, L277,
A281, and T282) at the extracellular transmembrane boundaries of the receptor have effects
on binding affinity and interactions with α-factor. According to the photo-reactive and
chemical crosslinking results from our lab (1, 22, 23, 35, 36), several residues (F55, R58,
C59, Y193, and K269) of Ste2p have been identified to interact directly with the ligand and
possibly reside at the binding pocket of of Ste2p for α-factor. We have also developed
some preliminary evidence that a residue (or residues) in extracellular loop 1 flanking
transmembrane domain 2 and transmembrane domain 3 interacts with the seventh residue
of α-factor. Overall, α-factor binds or interacts with a number of residues on its receptor
Ste2p to induce changes in the structure of the receptor from the inactive state to an
active conformation.
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After the ligand binds, confromational changes occur in Ste2p to “loosen” the
resting structure to an active form. Many residues (L102, N105, S108, Y111, T114, N132, M180,
Y203, F204, N205, L264, Y266, and D275) have been observed to play critical roles in Ste2p
activation (29, 37, 38). According to the preliminary data from our lab, we have
discovered possible interactions between residues at the transmembrane domains (R58Q135 and H94-E143) when the receptor is in its active conformation. Through cysteine
mutation and disulfide crosslinking of Ste2p in the absence and presence of α-factor, we
have also determined a rotational and transitional movement in transmembrane domain 5
and 6 of actived Ste2p in concert with the activation of heterotrimeric G proteins (Gpa1p
and Gβγ subunits).
The intracellular loop 3 (6) and C-terminus (39) of Ste2p modulate the activities
of the G protein complex. We identified five Ste2p residues (L228, S243, L247, L248, and
I249) at the cytoplasmic ends of transmembrane domain 5 and 6 that interact with five
residues (Q463, N465, K467, I469, and G470) at the C-terminus of Gpa1p. After the activation
of Ste2p, the conformational changes of the receptor leads to a rotational and tarnsitional
shift of Gpa1p, this results in about 5 Å withdrawal movement of Gpa1p away from the
transmembrane core of Ste2p. The resultant conformational change of Gpa1p allows
dissociation of GDP in exchange of GTP (40). The Gβγ subunits then dissociate from
GTP-activated Gpa1p and transmit the signal to the MAP kinase cascade (41) and
downstream effectors, which leads to transcriptional activation of response genes,
changes in morphology, and cell growth arrest.
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Chapter 2
Future Studies
In these studies, we have applied three different crosslinking techniques in order
to understand structure of a G protein-coupled receptor in Saccharomyces cerevisiae
(Ste2p) and its interaction with the ligand (α-factor) and Gα protein (Gpa1p). First, pbenzoyl-L-phenylalanine (Bpa) was incorporated into extracellular part of Ste2p as a
means to capture α-factor (36). Bpa-labeled Ste2p was expressed successfully and two
constructs was able to crosslink with α-factor. Second, cysteine mutation and disulfide
bond cross-linkage were introduced to intracellular loop 3 (IL3) of Ste2p and C-terminus
of Gpa1p to investigate possible interactions. IL3 appeared to be at dimer interface (42)
and was associated with Gpa1p for conformational changes upon ligand binding. Third,
chemical crosslinker 3,4-dihydroxyphenylacetyl (DHPA) was used to label lysine residue
at position 7 of α-factor for crosslinking with Ste2p for determination of the binding
domain. DHPA peptide bound to Ste2p specifically and was able to trigger downstream
signaling. A region of Ste2p spanning from transmembrane domain 2-extracellular loop
1-transmembrane domain 3 (TM2-EL1-TM2) is likely to interact with the DHPA labeled
α-factor. Here in this chapter, I am going to talk about possible applications of these
techniques for future studies in order to understand the structure of Ste2p in both the
resting and activated state and its interaction with its ligand and with other proteins
including its Galpha-protein, intracellular regulatory proteins, and other membrane
proteins.
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Incorporation of p-benzoyl-L-phenylalanine (Bpa) into Ste2p
In order to understand the interaction between a peptide ligand and its cognate
GPCR, Ste2p had been used as a model system to study its binding pocket for α-factor.
Site-directed mutagenesis has been carried out in many studies (29-34) to determine
possible residues that are important for α-factor binding. Mutation of several residues at
the extracellular boundaries of TMs (S47, T48, T50, L102, F204, N205, Y266, D275, L277, A281,
and T282) of Ste2p have shown to affect binding activity with the ligand after
mutagenesis. Alpha-factor labeled with photo-reactive crosslinker (Bpa) and chemical
crosslinker (DOPA) has been applied in our lab to capture Ste2p (1, 21-23), and residues
R58, C59, and K269 were identified to be in close proximity to the binding pocket of the
receptor. For this particular aspect of studies, the method of incorporating unnatural
amino acid (Bpa) into Ste2p can be applied to substitute for these candidate residues to
capture α-factor. Bpa crosslinking is very specific to amino acids within close range (3 Å)
to Bpa and therefore has the advantage to define binding pocket of the receptor.
However, there are some disadvantages of Bpa incorporation. For example in our
study, we chose to incroporate Bpa into residues with similar aromatic functional group
or residues known to be tolerant to amino acid substitution. The side chain of Bpa may be
too large to substitute for some smaller amino acids in the receptor so that those receptors
will not yield natural interactions with the ligand. Also the system of unnatural amino
acid replacement with TAG stop codon mutation we used in our research is not perfect
since we encountered problems with “readthrough” expression and target protein
degradation. Nevertheless, new approaches to improve the efficiency of unatural amino
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acid incroporation has been developed (43), which should be very useful for studies of
protein-protein interactions.
According to previous studies from our lab, the functional role of residues in the
first extracellular loop (EL1) of Ste2p has been investigated by cysteine scanning
mutagenesis (37). Five mutants were identified to be either partially (L102C and T114C)
or severely (N105C, S108C, and Y111C) compromised in signaling.

Furthermore,

solvent accessibility of residues Y101C and Y106C decreased dramatically upon ligand
binding (44). It was proposed that EL1 plays an important role in conformational switch
that activates Ste2p and initiates signal transduction pathway. Similar to the active states
of other GPCRs (bovine rhodopsin and dopamine D2 receptor) (45, 46), upon ligand
binding, there might be a shift in position of the helical region of EL1 that forms an
activation pocket with the transmembrane (TM) domains. In addition, mutagenesis study
from Konopka’s group (26) has shown that some mutants (S141P, I153F, I169K, and
L222P) of Ste2p that contained substitution within the TM domains displayed a
significant increase in constitutive activity that was α-factor independent. These residues
on the contrary are important to hold the receptor in inactive state, possibly through
interacting with other residues in different TM domains. In order to identify possible
interactions between EL1 and other TM domains and within TM-TM domains in active
and inactive states, incorporation of Bpa into EL1 and suggested TM residues can be
applied for photoaffinity crosslinking. With the addition of chemical or enzymatic
digestion, Bpa crosslinking has great potential to determine possible binding domains.
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For another application of Bpa-labeled Ste2p, intracellular interacting proteins
may be identified. After ligand binds, Ste2p receptor is phosphorylated, ubiquitinated,
and internalized by actin-based endocytic machinery. The intracellular proteins involved
in these regulatory interactions can be “captured” by Ste2p labeled in the C-terminus or
intracellular loops. Enrichment and mass spectrometry of these crosslinked proteins can
lead to determination of the intracellular “interactome” both in the resting and activated
(α-factor addition) states. Also, clathrin (Chc1p), which is associated with formation of
internalizing cargo for endocytosis, was found to co-localize with Ste2p (47). It is
possible that clathrin interacts with Ste2p and forms an endocytic complex for trafficking
inside the cell.
A novel application of Bpa-labeled Ste2p would be to apply Bpa-mediated
crosslinking to capture other membrane-bound proteins that are associated with Ste2p
during ligand-mediated cell signaling or during mating. There is a pheromone-dependent
interaction between Ste2p and Ste3p (the a-factor receptor) in later stages of fusion
between opposite mating types of S. cerevisiae that may be probed with a Bpa-labeled
Ste2p (48).
Finallly, Bpa-labeled Ste2p may be useful to identify TM-TM interactions of the
resting or activated state of Ste2. Transmembrane domains 1 (TM1), 4 (TM4) and 7
(TM7) of Ste2p were identified previously to be at the dimer/oligomer interface (49, 50).
The method of Bpa incorporation can be applied in Ste2p to confirm protein-protein
interaction with other proteins and to identify potential residue-to-residue binding sites.
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Cysteine Mutation for Disulfide Crosslinking of Residues in Transmembrane
Domains

Figure 6.1 Two-dimensional structural model of the transmembrane region of the αfactor receptor (26). The seven helices are arranged according to the structure of
rhodopsin. Solid lines between Asn84 and Gln149, Val223 and Leu247, and among
Gln253, Ser288, and Ser292 indicate intramolecular interactions suggested by
mutagenesis studies (7, 26, 51).

Comparison of functional equivalent regions between rhodopsin and Ste2p has
revealed that there are several similarities of the polar amino acids in the transmembrane
(TM) domains which might play essential roles for TM helix interaction and helix folding
(11). According to mutagenesis and molecular modeling studies (Figure 6.1), possible
interactions within the core of TM helix bundle have been predicted (26, 51). Residue
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Asn84 in TM2 is likely to interact with Gln149 in TM3 (N84-Q149) based on the
observation that mutants in both residues displayed strong constitutive activity (26).
Cysteines substitution at position Val223 in TM5 and position Leu247 (V223-L247) in
TM6 formed a disulfide bond indicating an interaction between TM5 and TM6 (7).
Residue Gln253 in TM6 was proposed to interact with Ser288 and Ser292 in TM7 (Q253S288 and Q253-S292) also based on constitutively active mutants (51). The structural model
shows possible orientation of Ste2p in inactive state according to the interactions bewteen
TM2-TM3, TM5-TM6, and TM6-TM7 domains.
On the other hand, according to preliminary data from our lab of residue
swapping in TM domains, some residue interactions in TM domains occurs after ligand
binding, which suggests that interfering with TM interaction in the active conformation
might lead to loss of function for Ste2p activation. In the active state of Ste2p, Arg58 in
TM1 was found to potentially interact with Gln135 in TM3 (R58-Q135); His94 in TM2 is
likely to interact with Glu143 (H94-E143). In conclusion, the polar residues in TM domains
play important roles either to hold Ste2p in the inactive state (N84-Q149, V223-L247, Q253S288 and Q253-S292) or to promote conformational switch of Ste2p that initiates signal
transduction pathway (R58-Q135 and H94-E143). In order to test these proposed interactions
of polar residues in TM helix of Ste2p, cysteine mutation for disulfide crosslinking can
be applied to examine these TM residues. This method has been applied successfully to
capture the interaction of polar residues between Asn205 at TM5 bounday and Tyr266 in
TM6 (N205-Y266) (25). Cysteine mutation has the advantage to substitute specific residues
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of interest and disulfide crosslinking can determine whether they are close enough (2-3
Å) for possible interaction to occur.

Incorporation of 3,4-dihydroxyphenylacetyl (DHPA) into α-factor and Ste2p
In Part V of this dissertation, I have presented the crosslinking result of 3,4dihydroxyphenylacetyl (DHPA) labeled α-factor and Ste2p. After digestion with
cyanogen bromide, a crosslinked band at 10-15 kDa was detected in the Western blot
probed with NeutrAvidin, which was concluded to be at the region between
transmembrane domain 2 and 3 flanking extracellular loop 1 (TM2-EL1-TM3, T72-M165).
The band was purified and confirmed by matrix-assisted laser desorption/ionization
(MALDI) mass spectrometric analysis. Until now, the exact binding residue of this
fragment with Bio-DHPA7 α-factor has not yet been identified. It was suggested that the
position 7 side chain of α-factor is more likely to interact with a pocket formed by
extracellular domains of Ste2p (52). Therefore, a series of site-directed mutagenesis at
TM2-EL1-TM3 region should be performed to identify the exact binding site. Multiple
steps of purification (His-Nickel and FLAG resin) and digestion (cyanogen bromide and
trypsin) should be considered in order to enrich the crosslinked fragment, which then can
be subjected to tandem mass spectrometric analysis (MS/MS) (22) for detailed
sequencing in order to confirm the exact binding site.
An alanine scanning of α-factor by replacing each residue with Ala amino acid
has been performed in order to understand the role of each residue of the peptide (53).
Residues near the N-terminus (position 2, 3, and 4) are found to be important for receptor
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activation and the ones near the C-terminus (position 11, 12, and 13) are important for
binding with Ste2p. The center of α-factor contains a Pro-Gly sequence (position 7, 8, 9
and 10), which is likely to promote a β-turn and help to orient the binding and signaling
domains of the pheromone. The photoreactive crosslinker p-benzoylphenylalanine (Bpa)
has been incorporated in to different positions of α-factor (1, 21). Bpa-labeled α-factor
analogs displayed different affinities when binding with Ste2p and only a few (Bpa1,
Bpa3, and Bpa13) of them was used to crosslink with the receptor. Since previous studies
from our lab with DOPA and DHPA crosslinking have shown very prominent results (23,
42), scanning through every residue of α-factor with chemical crosslinkers DOPA and
DHPA should be considered in order to determine where it binds Ste2p. Furthermore,
agonists, antagonists, and synergists of Ste2p can also be labeled with DOPA or DHPA,
and then the binding site of Ste2p with different peptides can be evaluated.
The translational machinery to incorporate redox-active DHP group (3,4dihydroxyphenylalanine, DOPA) into proteins in E.coli has been optimized (54). We
anticipate that future efforts from other labs will optimize DOPA or DHPA incorporation
into targeted residues of a yeast protein by using orthogonal tRNA-aminoacyl tRNA
synthetase pairs. The side chain of DOPA and DHPA has the advantage to crosslink
specifically with certain amino acids (cysteine, histidine, and lysine) (24) and therefore
can be used as an alternative to Bpa crosslinking. According to our previous results,
chemical crosslinkers, DOPA and DHPA, normally display stronger crosslinking signal
than photo-reactive Bpa. Therefore, development to incorporate DOPA or DHPA into
yeast proteins, such as Ste2p, has a great potential to identify residue-to-residue
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interactions. In the extracellular side, DHPA-labeled Ste2p can be used to capture the
ligand and help define the binding pocket. In the intracellular side, DHPA can crosslink
and help to identify Ste2p interacting proteins.
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